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1. ABSTRACT 
The Hedgehog (Hh) signalling pathway is essential for numerous processes during 
embryonic development including development of the skin and pancreas. Dysregulation of 
Hh-signalling during development might be lethal and may lead to cancer in adult cells. This 
pathway is important in several types of cancers including cancers in the pancreas, brain and 
skin. The best known examples of excessive Hh-signalling causing cancer are the frequent 
mutations and dysregulation observed in basal cell carcinoma (BCC), a type of skin cancer. 
The Hh-pathway is considered as a very promising target for new anti-cancer treatments and 
increased knowledge of this pathway may lead to new strategies of cancer treatment.  
Hedgehog (Hh), Patched (Ptch), Smoothened (Smo), Suppressor of fused (Sufu), fused (Fu) 
and Gli are signalling proteins in the Hh-pathway. Mutations in genes encoding these 
members of the Hh signalling pathway may lead to cancer. Smoothened is a seven 
transmembrane protein which has been studied in this current project and shows several 
characteristics of being a G-protein-coupled receptor (GPCR). Fourteen somatic mutations 
in Smo have been identified. Five of these mutations have been analysed herein and one of 
these mutations was generated as part of the thesis work (K575M-Smo).  
First, PCR-based mutagenesis was performed to generate a mutated version of Smo, 
K575M-Smo. Subsequently the PCR-product containing K575M-Smo was inserted into the 
pEF.6 vector.  
Secondly, K575M-Smo, four other mutants (R484W-, L514F-, S533N- and W535L-Smo) 
and Smo wt were sub-cloned from the pEF.6 vector into the mammalian expression vector 
p3xFLAG-CMV-10.  
NIH/3T3 mouse fibroblast cells were stably transfected with the following constructs: 
p3xFLAG-CMV-10 vector (empty vector control), p3xFLAG-CMV-10 R484W-, L514F-, 
S533N-, W535L-, K575M-Smo and Smo wt, to analyze the signalling properties of the 
different mutated versions of Smo. From each transfection, six independent monoclonal cell 
lines potentially harbouring the transfected plasmid were isolated, and different experiments 
were performed, including real-time reverse transcriptase polymerase chain reaction (RT-
PCR), Western blotting and reporter gene assay. 
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Taken together, the K575M-Smo encoding plasmid was successfully generated in the 
laboratory. Initial experiments showed a trend of constitutive activity of W535L-Smo. Based 
on the variable data from real-time RT-PCR experiments, it is not possible to make 
conclusions about the signalling properties of the various Smo mutations, and further studies 
are needed.   
10 
2. BACKGROUND 
2.1 CANCER 
Cancer (malignant neoplasm*) is a class of diseases where a group of cells undergo 
uncontrolled multiplication and may spread within the body. Cancer may affect people at all 
ages, but the risk of developing cancers increases with age. Nearly all cancers are caused by 
abnormalities in the genetic material of the cells, but cancer may also occur from 
environmental factors as smoking and sun-exposure (UV-light) on skin. The major cause of 
death in the developed nations is cancer, and at least one in five of the population of Europe 
and North America can expect to die from cancer. Genetic changes that lead to cancer are 
activation of proto-oncogenes** to oncogenes, and inactivation of tumour suppressor genes. 
These changes are result of point mutations, gene amplification, loss of heterozygosity or 
chromosomal translocation [1]. 
*Neoplasm means “new growth”. ** Oncogene is a gene that helps turning a normal cell into a cancer cell due 
to mutations or increased expression. 
2.1.1 Hedgehog signalling in cancer 
The Hedgehog (Hh) signalling pathway is required for cell proliferation and differentiation, 
and plays a central role during embryogenesis and during development of the foetus. For the 
most part the activity of the pathway is reduced after embryogenesis, but there are examples 
of pathway activity in some adult tissues, like adult stem cells in the brain, pancreas and 
skin. Abnormalities like sporadic mutations in the Hh-pathway during development can be 
lethal and may lead to cancer in adult cells. The best known examples of excessive Hh-
signalling causing cancer are the frequent mutations and dysregulation observed in the most 
common form of skin cancer, basal cell carcinoma (BCC) [2-4]. 
The Hh signalling pathway was confirmed linked to tumourigenesis in 1996 when a human 
homologue of Drosophila patched (Ptch1), a component in the Hh-pathway, was found to be 
mutated in nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin’s 
syndrome [5, 6]. Gorlin`s syndrome is an autosomal congenital condition characterised by 
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the presence of multiple BCCs of the skin, abnormalities in facial and skeletal development, 
and a predisposition to medulloblastoma and rhabdomyosarcoma [5].  
Point mutations in genes encoding members of the Hh signalling pathway may lead to 
dysregulation of the signalling pathway and causes cancer in different tissues like skin, 
pancreas, brain and breast [7] (Figure 2.1). 
Cancer types containing mutations in Hh-pathway molecules include [7]: 
o Basal cell carcinoma (BCC)  
o Medulloblastoma  
o Rhabdomyosarcoma  
Cancer types containing dysregulation of Hh-signalling are present in [7]: 
o Breast cancer 
o Pancreas cancer 
o Lung cancer 
o Ovary cancer 
o Oesophagus cancer  
o Stomach cancer 
o Liver cancer 
o Prostate cancer 
o Colon cancer 
o Glioma [8] 
 
Figure 2.1: Overview of different types of cancer caused by dysregulation of Hh-signalling. Dysregulation of 
Hh-signalling causes cancer in different tissues (Adopted from Pasca di Magliano and Hebrok, Nat Rev 
Cancer, 2003 [3]). 
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Skin cancer is the most common cancer in the Western world and BCCs account for 90% of 
all skin cancers. Sporadic BCCs are rarely found before the age of 20 years but thereafter the 
risk of developing BCCs increases with age [9]. The current understanding of the 
development of BCCs has increased with the understanding of mutations that are known to 
activate Hh signalling pathways genes related to BCC [10]. In BCCs there are identified 
mutations in several components of the Hh-pathway (like Hedgehog (Hh), Smoothened 
(Smo) and Patched (Ptch) genes) resulting in aberrant Hh-signalling [9].  
2.2 THE HEDGEHOG SIGNALLING PATHWAY 
The Hh-pathway takes its name from the polypeptide ligand activating the pathway, the 
intercellular signalling protein called Hedgehog, which was first discovered in the two-
winged insect Drosophila melanogaster [11-13]. The main differences between the Hh-
pathway in insects and vertebrates are the increasing numbers of related genes present in 
vertebrates, and the Hh-pathway in vertebrates is less studied and more complex than in 
insects [2, 14-17]. In vertebrates (e.g. human and mouse) there are currently identified three 
Hh proteins (called Sonic (Shh), Indian (Ihh) and Desert (Dhh)), two patched genes (called 
Ptch1, Ptch2) and three cubitus interruptus-like proteins (called Gli1-3) [2, 13, 18, 19]. 
Cubitus inerruptus (Ci) is a gene regulatory protein present in Drosophila [4]. Shh is the 
most potent of the three ligands and most frequently expressed in embryonic and adult 
tissues [8, 20, 21].  
In this thesis, the term Hh will be used to refer to all three Hh isoforms. If there are different 
effects of the three isoforms, Shh will be considered the reference substance if not otherwise 
stated. The experiments in this project are performed in mouse fibroblast cells, thus the main 
focus of this thesis will be the vertebrate Hh signalling pathway, although most of what is 
known about the downstream signalling of the Hh-pathway comes from genetic studies in 
flies [4]. Additionaly, Smoothened (Smo), a component in the Hh-pathway, is analysed in 
this project and will be described in detail in this thesis. 
The Hh-pathway is activated when Hh (ligand) binds to its receptor, Patched (Ptch) (Figure 
2.2). In the absence of ligand, Ptch normally functions as a tumour suppressor that binds and 
represses Smo from activating downstream components and transcription of target genes 
(Figure 2.2; left). Ligand binding to Ptch results in de-repression of Smo which activates the 
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transcriptions factor Gli, allowing Gli to enter into the nucleus and regulate the expression of 
its target genes (Figure 2.2; right) [3].  
 
Figure 2.2: Hedgehog signalling pathway. Left figure shows the signalling pathway in the absence of Hh-
ligand. Hh-ligand-dependent activation of the pathway is shown in the right panel (Adopted from Pasca di 
Magliano and Hebrok, Nat Rev Cancer, 2003 [3]). 
Hedgehog (Hh; Fig. 2.2) is an unusual secreted protein which undergoes autocatalytic 
cleavage and covalent lipid modifications [5]. Hh plays an essential role in the Hh signalling 
pathway involved in cell type specification, pattering and the regulation of cell proliferation 
and differentiation in almost all tissue types during development [9]. The active form of Shh 
is unusual in that it is covalently coupled to cholesterol. The cholesterol becomes attached to 
Shh during the autocatalytic cleavage process [4]. The protein is also modified by the 
addition of a fatty acid chain, which also is required for its signalling activity. Shh is able to 
signal at short-range as well as at long-range in multiple context, which is controlled by the 
lipid modification of the Hh molecule (See section 2.2.1) [22, 23]. Two transmembrane 
proteins, Patched (Ptch) and Smoothened (Smo), mediate the response to Hh [24]. 
Patched (Ptch; Fig. 2.2) is a twelve-pass transmembrane protein and binds Hh with high 
affinity [25, 26]. The two isoforms Ptch 1 and Ptch 2 will be referred to as Ptch in this thesis. 
In the absence of a Hh signal, Ptch inhibits the activity of Smo (Figure 2.2., left), and this 
inhibition is repealed when Hh binds to Ptch (Figure 2.2; right) [4]. Ptch represses 
transcription of Hh target gene and is considered to be a tumour suppressor gene [3, 8, 15]. 
Mutation in the Ptch gene may lead to excessive Hh-signalling, which may cause cancer 
[24]. BCC may be a consequence of mutations in the gene encoding Ptch, and have been 
identified in at least half of all sporadic BCC [27]. 
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Smoothened (Smo; Fig. 2.2) is a seven-pass transmembrane protein and a transducer of Hh-
signalling, resulting in activation of downstream components of the Hh-pathway (Figure 2.2; 
right). Smo shows several characteristics of being a G-protein-coupled receptor (GPCR). 
However the Smo protein does not bind ligands (read: Hh) [25, 28-30]. Unregulated Smo-
signalling may cause cell proliferation, and constitutively active variants of Smo may be 
oncogenic, and cause cancer, e.g. BCC [3]. 
Gli (Fig. 2.2): Three vertebrate Gli genes have been identified; Gli1, Gli2 and Gli3 [13, 18, 
19]. The Gli proteins are zinc-finger transcription factors and downstream mediators of the 
Hh response, just like Cubitus interruptus (Ci) in Drosophila [25, 31, 32]. Gli1-3 exhibit 
distinct repressor and activator functions depending on cellular context [3, 33]. Gli1 is 
mainly a transcriptional activator, and is therefore upregulated in response to Hh [25, 34]. 
Gli2 and Gli3 contain potent repressor domains and are proteolytically cleaved to forms 
having either activator or repressor function [5, 35]. The proteolytic processing of Gli 
depends on a large multiprotein complex. The complex contains the serine/threonine kinase 
Fused (Fu) and an adaptor protein called Suppressor of Fused (Sufu). This complex is 
located in the cytosol of the vertebrate cells [3, 4, 34]. Ectopic expression of Gli has been 
shown to cause glioma, a CNS tumour derived from glia cells [8]. 
Fused (Fu; Fig.2.2): The gene encodes a serine-threonine kinase that functions as a positive 
regulator of the transcription factors of the Gli-family in the Hh-pathway [5, 36]. Fu is 
required for the regulation of the Hh-pathway, but the mechanistic role of Fu remains 
unknown [37]. 
Suppressor of Fused (Sufu; Fig. 2.2) is a negative regulator of Gli-activity in the Hh-
pathway [38-41]. Sufu is thought to be important for the shuttling of the Gli proteins 
between the cytoplasm and nucleus [9].  Sufu is a tumour-suppressor gene interacting with 
Fu and Gli [40, 42]. Loss-of-function mutations in Sufu have been identified in some 
medulloblastoma cells, a tumour in CNS [38].  
Hedgehog interacting protein (Hip; Fig. 2.2) is an inhibitor of Hh-signalling only found in 
vertebrates. Hip encodes a membrane-bound glycoprotein that binds Hh, appearing to be a 
negative regulator of Hh-signalling as overexpression of Hip in vertebrates reduces the Hh 
signalling pathway activity [43]. 
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2.2.1 Maturation of Sonic hedgehog protein (Shh) 
The Hh-family of secreted proteins are subjected to different autoprocessing and 
posttranslational modifications in order to be fully activated [9, 44]. Shh is encoded by a 
single gene and undergoes autocatalytic cleavage as well as covalent lipid modification [5]. 
The autocatalytic protein is synthesized as a 45 kilodalton (kDa) precursor protein which is 
divided into two domains by intramolecular cleavage (Figure 2.3).  
 
Figure 2.3:  Maturation of the Shh protein (Modified figure from Daya-Grosjean et al, Cancer Letters, 2005 
[9]). 
The C-terminal portion of the precursor catalyzes the catalytic process, generating a 19 kDa 
N-terminal signalling domain (Shh-N) and a 25 kDa C-terminal domain (Shh-C). Shh-C has 
no known function other than catalyzing the autoproteolytic cleavage. During the 
autocleavage process, a cholesterol moiety is covalently attached to the last amino acid of 
Shh-N (Figure 2.3), increasing the hydrophobicity. The hydrophobic cholesterol moiety is 
thought to bind Shh to cell membranes. The hydrophobicity of the signal domain is further 
increased by attaching another lipid moiety (palmitoyl) to the highly conserved N-terminal 
cysteine residue which is dependent on the cholesterol addition [9, 43, 44]. The Shh-N signal 
domain may either be attached to the plasma membrane of the producing cell or transported 
to responding cells through different mechanisms. Shh acts in an autocrine manner, affecting 
the cells in which it is produced, as well as in a paracrine manner, affecting cells positioned 
next to the producing cells. Shh can also diffuse for long range signalling through 
extracellular space towards responsive cells by interacting with heparan sulphate 
proteoglycans, which also allow presentation of Shh to receptors on target cells [7, 9, 15, 45, 
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46]. Another mechanism for long range signalling of Shh is presented in an article of Zeng et 
al [47]. They showed that the Shh signal peptide multimerises at lipid rafts with the lipid 
adducts sequestered at the centers, rendering it soluble and able to diffuse for long range 
signalling [9, 47]. Another protein involved in regulating Shh-signalling is the Hh-
interacting protein (Hip), which is a membrane bound glycoprotein that binds Shh and 
moderates its response. Hip has a binding affinity for Shh comparable to that of Ptch, 
suggesting the existence of an additional negative feedback mechanism for regulating 
responses to Shh-signalling [48].  
2.2.2 The Hedgehog signalling cascade 
The exact details of the Hh signalling pathway are still not fully understood, but the current 
model proposes that the Hh signalling cascade is initiated by Hh-binding to the Ptch 
transmembrane protein expressed on the responsive cells. Ptch inhibits the activity of Smo, 
presumably by preventing translocation of Smo to the primary cilium at the cell surface of 
vertebrate cells. The Ptch-mediated inhibition is repealed following ligand binding. In the 
presence of ligand, Smo becomes active and initiates the signalling cascade that results in 
the activation of the Gli transcription factors (Figure 2.2; right) [3, 7, 9, 22, 49]. The 
mechanisms by which the activation of Smo is translated into signals that converge on the 
Gli transcription are not fully understood. It is known that once the Hh-pathway is activated, 
the interactions between Smo and the cytoplasmic multiprotein complex formed by Fu, Sufu 
and Gli are dispersed, allowing Gli to enter the nucleus, where it may bind DNA and 
regulate the expression of its target genes [2, 3, 7, 50]. The genes targeted by Hh have been 
identified to include Gli1, Ptch1 and Hip. Gli1 serves as a positive feedback for the Hh-
pathway, and Ptch1 and Hip results in negative feedback [23]. Genetically, Hh, Smo, and Fu 
are positively acting components in the pathway, whereas Ptch, Hip and Sufu have a 
negative role [5].  
2.3 G-PROTEIN-COUPLED RECEPTORS 
G-protein-coupled receptors (GPCRs) are one of the largest known families of membrane 
signalling proteins, and are also known as metabotropic receptors or seven-transmembrane 
(heptahelical) receptors, according to their secondary and tertiary structures. Through 
17 
conformational changes, GPCRs transmit extracellular ligand-induced signals to the 
intracellular environment through activation of one or more heterotrimeric G-proteins that 
subsequently regulate intracellular enzymes. The GPCRs are involved in a wide variety of 
physiological functions and are one of the major targets for currently used drugs and new 
drug development [51, 52]. Among membrane-bound receptors, the GPCR family is 
certainly the most diverse. The GPCR superfamily consists of more than 1000 members and 
the receptors are divided into subfamilies based on sequence homology, ligand structure, and 
receptor function. As mentioned previously Smo resembles a G-protein-coupled receptor, 
and activating Smo mutations may lead to unregulated activation of the Hh-pathway and a 
physiological consequence may be cancer formation [7]. Increased knowledge of the GPCR-
like protein Smo and mutated variants of Smo will extend our understanding of the 
physiological and pathological processes regulated by the Hh signalling pathway. The Hh-
pathway is considered as a very promising target for new anti-cancer treatments and 
increased knowledge of Hh/Smo/Gli-mediated signalling may lead to new strategies of 
cancer treatment.  
2.3.1 Structure and classification of G-protein-coupled receptors 
Based on certain conserved amino acid sequences three major families (I, II and III) and 
several subfamilies of GPCRs have been defined [53]. Family I, the largest group, includes 
receptors related to rhodospin, comprising most monoamine and neuropeptide receptors. 
Family II contains receptors related to the secretin/glucagon/calcitonin receptors, and family 
III is the smallest group related to the metabotropic glutamate receptors [54, 55]. The 
different families of GPCRs share essentially no sequence similarities, but they all share 
some common features. GPCRs consist of a single polypeptide chain that have an 
extracellular amino terminal (N-terminal) domain, a central core domain and an intracellular 
carboxy terminal (C-terminal) domain. The central core domain consists of seven 
transmembrane (7TM) α-helices, which are linked by alternating intracellular (i1-i3) and 
extracllular (e1-e3) loops (Figure 2.4).  
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Figure 2.4: General secondary structure of GPCRs. The seven transmembrane spanning domains are linked by 
alternating intracellular (i1-i3) and extracellular (e1-e3) loops. The N-terminal tail of the receptor is 
extracellular and the C-terminal tail is intracellular (Modified figure from Hollmann M.W. et al, 
Anesthesiology, 2005 [51]). 
In addition to sequence variations, GPCRs differ in their length of the 7TM α-helices, the 
extracellular N-terminal domain, the intracellular C-terminal domain and their intracellular 
loops, as well as functions of these domains [51]. Among the extracellular loops e1 has the 
most steady loop size and the other two extracellular loops (e2 and e3) have more variable 
sizes. Most of the GPCRs have two cysteine residues in the e1 and e2 forming a disulfide 
bond important for the packing and stabilisation of the native receptor conformation [56]. 
The extracellular receptor surface varies substantially among different GPCRs. This area 
consisting of the N-terminal domain, the extracellular loops and the extracellular portions of 
the 7TM α-helices is important for ligand binding (Figure 2.4). The intracellular receptor 
surface consisting of the C-terminal domain and the intracellular loops are involved in G-
protein recognition and activation (Figure 2.4) [54].  The i3 is larger than the other loops and 
interacts with the G-protein. G-proteins are intracellular membrane associated proteins 
consisting of three subunits, the αβγ-heterotrimer. They are called G-proteins because of the 
α-subunits interaction with the guanine nucleotides GTP and GDP. Activated G-proteins 
regulate intracellular enzymes. The C-terminal tail is also involved in controlling 
desensitisation and internalisation of the receptors (Figure 2.4), due to phosphorylation and 
palmitoylation sites located in the tail [51]. Desensitisation is loss of functional response 
from an agonist activated receptor, and internalisation is reduction in surface receptor 
number, determined by a combination of the effects of endocytosis and recycling [57]. A 
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conformational change of the 7TM core regions is probably responsible for activation of 
GPCRs [1, 56, 58]. 
2.3.2 GPCR constitutive activity  
GPCRs may spontaneously isomerise from inactive to active receptor conformation, leading 
to agonist-independent activation of heterotrimeric G-proteins. When GPCRs are active in 
absence of ligand they are called constitutively active receptors. Somatic mutations in 
GPCRs may lead to constitutively active receptors, and mutated GPCR genes may be 
disease-causing through the expression of inactive or constitutively active receptors. These 
mutations appear to decrease the energy barrier required for the isomerisation from the 
inactive to the active state of the receptor, thus causing increased signalling in the absence of 
ligand. Mutations causing increased ligand independent activity of GPCRs are frequently 
located in the intracellular part of the seventh transmembrane domain, but other locations for 
such mutations have also been reported [59-62].  
2.3.3 Smoothened as a GPCR-like protein  
Smo is related to the GPCR family II. Smo is a therapeutic target for several candidate drugs 
in the treatment of Hh-related diseases [63]. The Smo GPCR-like protein is essential for 
transduction of the Hh-signal across the cell membrane. 
The Hh signalling pathway differs from the common mechanisms of GPCR activation, 
because Smo lacks the ability to directly interact with the ligand. Smo uses Ptch as the 
receptor for the Hh-ligand. Ligand binding to Ptch releases Smo from Ptch inhibition 
inducing a change in conformation of Smo that may lead to coupling to and activation of G-
proteins. The third intracellular loop and the seventh transmembrane domain of Smo are 
important for coupling to heterotrimeric G-proteins. Mutations in these regions may cause 
Smo to become constitutively active [2]. One mutation studied in this thesis (W535L-Smo) 
has been shown to result in constitutively active Smo. The W535L mutation resides in the 
seventh transmembrane region of the Smo protein (Figure 2.5) [5, 25]. The mechanisms by 
which the activation of Smo is translated into signals that converge on the Gli transcription 
factors are not fully understood [50].   
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Smo has a long extra-cellular N-terminal domain about 250 amino acids long, containing a 
conserved cysteine-rich domain (CRD). The cysteines in this domain are essential for 
achieving the correct tertiary structure, and play an important role in Smo-regulation. 
Occurrence of correct disulphide bridges within the CRD is required to accomplish Smo-
activity. The disulphide bridges are also required for the interaction between Smo and Ptch 
[2, 55, 56].  
Traditionally, GPCRs have been thought to act as monomers, but it is now also accepted that 
GPCRs may exist as multimers. How the GPCR-like protein Smo is activated remains 
poorly understood, but fluorescence resonance energy transfer (FRET) studies suggest that 
Smo may exist as a constitutive dimer and that Hh induces a conformational change, leading 
to increased proximity of the two Smo C-terminal tails. The Smo C-terminal tail is essential 
in activating Smo. Smo proteins contain multiple conserved clusters of basic residues in their 
C-terminal tails, including a long stretch of arginine-lysine (Arg/Lys) residues in the middle 
region. Mutating this long stretch of Arg/Lys residues to alanine (Ala) may result in 
constitutively active Smo. Smo may employ an Arg/Lys-cluster to regulate its conformation 
and activity [64]. The K575M-Smo mutation studied in this thesis is located in this lysine-
rich stretch of the Smo C-terminal tail. Finally, the activated Smo-dimers would interact 
with the Fu-Sufu-Gli complex, inducing Sufu phosphorylation by Fu, and activation of the 
Gli transcription factors [64]. 
2.4 MUTAGENESIS IN SMOOTHENED  
Presently, fourteen somatic mutations are identified in Smo (Table 2.1). Two additional 
mutations have also been reported. These mutations have not been included in table 2.1, 
because one of the mutations (A404A-Smo) is silent, and the R168H-Smo mutation 
described by Yan T. et al [65] may not represent a somatic mutation and is not registered in 
the Catalogue Of Somatic Mutations In Cancer (COSMIC) database. The identified somatic 
mutations in Smo are located throughout the entire protein. Many of the mutations are 
typically UV-light induced mutations comprising C→T or CC→TT mutations. Most of the 
mutations in Smo have been identified in BCCs and the main risk factor for BCC is sun light 
exposure, especially for those with a lighter skin. The somatic mutations in Smo are also 
identified in the large intestine and CNS. The tumours containing the mutations are all 
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carcinomas, except mutation S533N, which is identified in medulloblastoma. According to 
the model of Hh-signalling, loss-of-function mutations in Ptch will de-repress Smo, leading 
to constitutive activation of the pathway. The same result would be obtained by gain-of-
function mutations in Smo. Such activating mutations have been found in BCC and 
medulloblastomas [5, 9]. 
2.5 AIMS OF THE PRESENT STUDY  
This study is part of a broader project, aiming at analysing the signalling properties of 
somatic mutations found in Smo. Specifically, one mutated version of Smo (K575M-Smo) 
will be generated in the laboratory and the signalling properties of this and four additional 
mutated version of Smo will be analysed. 
The following five mutated variants of Smo will be studied in the current project: R484W-, 
L514F-, S533N-, W535L- and K575M-Smo (Figure 2.5; Table 2.1). R484W and L514F-
Smo are UV-light induced mutations (CC→TT mutations) identified in BCC and located in 
extracellular loop 3 (e3) [66]. The e3 loop in GPCRs is known to be responsible for ligand 
binding [54]. However, since Smo does not bind the ligand activating the pathway, the effect 
of these mutations will be difficult to predict [67]. The e3 in Smo may be responsible for the 
Ptch interaction and the two mutations situated in this extracellular loop may alter the 
signalling properties of Smo. Two of the mutations which will be analysed in the laboratory 
are located in the seventh transmembrane domain; S533N- and W535L-Smo [65]. 
Reifenberger J et al. [67] identified the S533N-Smo mutation in a primitive neuroectodermal 
tumour (PNET), a G→A mutation at nucleotide 1598 that leads to the exchange from serine 
to aspargine at codon 533 [66, 67]. The W535L-Smo mutation has been identified in four 
different studies addressing Smo modifications in sporadic BCCs [66-69]. The W535L-Smo 
mutation is a UV-light induced mutation (C→T mutation) and known to be constitutively 
active and oncogenic, resulting in cancer in the skin [5, 70, 71]. W535L-Smo has been 
shown to result in receptors no longer sensitive to Ptch inhibition and thus constitutively 
active [66-68, 72]. In the majority of GPCRs, the codon corresponding to codon 535 in Smo 
encodes a conserved tyrosine residue, the function of which is to keep these receptors in a 
latent state by the formation of a polar pocket. Disruption of this site by mutation of Smo has 
been shown to result in constitutive Hh-signalling important in BCC development [65]. 
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Furthermore, the homology with GPCRs indicates that the seventh transmembrane domain 
and the third intracellular loop of the Smo protein are required in the activation of 
downstream signalling. The W535L-Smo constitutes a hot spot for Smo protein 
modifications, and it has been shown to cause constitutive activity [69]. The K575M-Smo 
mutation, which will be generated in the laboratory, was identified by Sicklick J et al. [73] in 
a cirrhotic liver-tumour in a 67-year-old female. The K575M-Smo mutation is an A→T 
mutation located in the C-terminal tail [73]. The Smo C-terminal tail is essential in 
activating Smo. The cytoplasmic tail and the intracellular loops of GPCRs are critical 
domains for the interaction with G-proteins, a step essential in signal transduction. The 
homology to GPCRs may suggest that the K575M located in the cytoplasmic tail of the Smo 
protein may alter Smo protein function. Modifications in this region of the protein may also 
be important in affecting receptor desensitisation or internalisation, as mentioned previously 
[65].  
In summary, it may be expected that the W535L-Smo mutation shows altered signalling 
properties. The signalling properties of R484W-, L514F-, S533N- and K575M-Smo are 
previously not known, and the goal of this thesis is to compare these mutated versions of 
Smo with Smo wildtype and W535L-Smo, the latter one known to show constitutive 
activity. 
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Table 2.1: The information of the different mutants is taken from the Catalogue Of Somatic Mutations In 
Cancer (COSMIC) database (http://www.sanger.ac.uk/genetics/CGP/cosmic/). The mutations highlighted in 
blue and bold have been analysed in this project. The plasmid construct encoding the K575M-Smo (dark blue) 
was generated as part of the thesis work whereas the mutated constructs in light blue was available.  
 
Figure 2.5: Secondary structure of the human Smo-receptor with the identified somatic mutations. The 
mutations marked in blue have been analysed in this project. The plasmid construct encoding the K575M-Smo 
marked dark blue was generated as part of the thesis work. 
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3. METHODS 
This chapter describes the methods used in this thesis. Buffers and solutions used in the 
methods are listed in the appendix (section 8.1 “Materials and recipes”). A general 
presentation of the methods used in these studies is given in this chapter while more detailed 
descriptions of the practical approach are presented in the appendix (section 8.2 
“Protocols”).  
3.1 OVERVIEW METHODS 
PCR-based mutagenesis was performed to generate a mutated version of Smoothened (Smo), 
K575M-Smo. The PCR-product containing the mutated Smo-sequence was digested with 
specific restriction enzymes and ligated into the equally cut pEF.6 Smo wt plasmid. To 
amplify the plasmid construct in large scales competent bacteria were transformed and DNA 
plasmid was isolated and purified. The DNA plasmid were analysed by sequencing.  This 
mutated version of Smo, K575M-Smo, and four other mutants R484W-, L514F-, S533N-, 
W535L-Smo (which were available in the laboratory), and Smo wt were inserted in the 
mammalian expression vector p3xFLAG-CMV-10. An EcoRI restriction site was generated 
in the Smo constructs to accomplish the insertion. These five mutated versions of Smo and 
Smo wt were digested with EcoRI and XbaI restriction enzymes and ligated in the equally 
cut p3xFLAG-CMV-10 vector. Competent bacteria were transformed with these plasmids, 
and plasmid DNA was isolated from the bacteria. Isolated and purified plasmid DNA was 
analysed by sequencing. The QIAGEN maxiprep plasmid purification kit was used for large-
scale plasmid preparations of these six DNA plasmids. NIH/3T3 mouse fibroblasts were 
stably transfected with the following constructs: p3xFLAG-CMV-10 vector (empty vector 
control), R484W-, L514F-, S533N-, W535L-, K575M-Smo and Smo wt in the p3xFLAG-
CMV-10 vector, to analyze the signalling properties of the different mutated versions of 
Smo. From each transfection, six independent monoclonal cell lines potentially harbouring 
the transfected plasmid were isolated, and different experiments were performed, including 
real-time polymerase chain reaction, Western blotting and gene reporter assay.  
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Flow chart: methods 
MUTAGENESIS REACTION 
K575M-Smo (Two PCR-reactions) 
↓ 
1. Digestion 
(K575M & pEF.6 Smo wt vector digested with Tth111I & Sph I) 
↓ 
2. Ligation 
 (K575M + pEF.6.Smo wt vector) 
↓ 
3. Transformation 
↓ 
4. Small-scale plasmid preparation 
↓ 
5. Quantification of DNA 
↓ 
6. DNA sequencing  
(Product: K575M-Smo pEF.6 Smo wt plasmid) 
↓ 
SUB-CLONING 
↓ 
1. Generation of restriction site 
 (Make EcoRI restriction site in R484W-, L514F-, S533N-, W535L-, K575M-Smo and Smo wt) 
↓ 
2. Digestion:  
The five mutated versions of Smo and Smo wt and p3xFLAG-CMV-10 vector digested with EcoRI & XbaI 
↓ 
3. Ligation:  
R484W-, L514F-, S533N-, W535L-, K575M-Smo and Smo wt + p3xFLAG-CMV-10 vector 
↓ 
4. Transformation 
↓ 
5. Small-scale plasmid preparation 
↓ 
6. Quantification of DNA 
↓ 
7. DNA sequencing 
 (Products: p3xFLAG CMV-10 R484W-, L514F-, S533N-, W535L-, K575M-Smo and Smo wt) 
↓ 
8. Large-scale plasmid preparation 
↓ 
TRANSFECTION 
p3xFLAG CMV 10 R484W-, L514F-, S533N-, W535L-, K575M-Smo and Smo wt + NIH/ 3T3 cells 
              ↓ + G418 
Stable transfection of NIH/3T3-cells with the five mutated versions of Smo and Smo wt. 
↓ 
Isolation of six monoclonal cell-lines of each mutant 
↓ 
ANALYSIS OF CELL EXPERIMENTS 
Real-time polymerase chain reaction (RT-PCR), Western blotting, and gene reporter assay 
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3.2 MUTAGENESIS REACTION 
A lysine was mutated to a methionine at amino acid residue at position 575 in the Smo wt 
receptor, resulting in the K575M-Smo-receptor. This mutated version of Smo was generated 
by using mainly two PCR-reactions, where the first PCR-reaction (PCR-I) occurs in two 
independent tubes (Figure 3.1). Smo wt was used as template in PCR-I generating PCR-
products harbouring the desired mutation. These two PCR-products were used as templates 
in a new PCR-reaction (PCR-II) generating a longer PCR-product that was cut with specific 
restriction enzymes, Tth111I and SphI, and ligated in the equally cut pEF.6 Smo wt plasmid. 
The DNA molecule was cut because these enzymes break the phosphodiester bonds that link 
one nucleotide to the next. Generally, selection of buffer is essential for selective cutting of 
the DNA, and the optimal temperature is usually 37˚C. Finally, the digested PCR-product 
and pEF.6 Smo wt plasmid were ligated by T4 DNA ligase. T4 DNA ligase catalyzed the 
formation of  phosphodiester bonds between the 3`-hydroxyl and the 5`-phosphate groups in 
nicked DNA.  
 
Figure 3.1: K575M-Smo mutagenesis reaction I and II.  The K575M-Smo was generated by two 
polymerase chain reactions (PCR-I & PCR-II). The first PCR-reaction (PCR-I) was performed in two separate 
tubes (1 and 2), and gave two products with the desired mutation using pEF.6 Smo wt as template and two sets 
of primer pairs (Primer pair 1; R199W-Forward (FW) and K575M-Reverse (Rev), primer pair 2; K575M-FW 
and P755F-Rev). The mutagenesis primers K575M-FW and K575M-Rev contain a “mismatch” which gave the 
desired mutation in the generated PCR-I products. In PCR-II, the two products from PCR-I served as 
templates, and the flanking primers from PCR-I, R199W-FW and P755F-Rev, were used to initiate the DNA 
synthesis.The polymerase chain reaction gave linear double-stranded DNA containing mutations. 
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PCR is an extremely sensitive method to amplify a specific DNA sequence in vitro. The 
method is based on the use of thermostable DNA polymerase to copy a DNA template in 
repeated cycles of replication, giving an exponential increase in the DNA-product. The 
method requires two specific primers, a thermostable polymerase enzyme and a dNTP mix, 
containing equal amount of dATP, dGTP, dCTP and dTTP.  
In an automated thermal cycler (PCR-machine) DNA was amplified by first heating the 
sample to 94˚C in order to separate the two strands, and the DNA was melted into single 
stranded DNA. Secondly, the temperature was lowered below the melting point of the 
primers allowing the primers to anneal to their corresponding DNA sequence. Finally, the 
temperature was increased to the optimum of the polymerase, usually 68-72˚C, allowing 
extension of the primers replicating the DNA (DNA replication). Typically, 20-30 cycles of 
reaction is required for effective DNA amplification, and each cycle doubles the amount of 
DNA. Within a few cycles the predominant product in the reaction is a DNA fragment 
corresponding to the sequence between the two primers. The thermostable Vent DNA 
polymerase enzyme that survives prolonged exposure to temperatures as high as 95˚C was 
used in this thesis. The Vent polymerase stays active after the denaturation steps in the PCR 
procedure and has proofreading activity. At temperatures this high normal DNA polymerase 
would have denatured together with the DNA. 
Table 3.1: Primer used in mutagenesis reactions, sub-cloning and DNA-sequencing (FW, forward primer; 
Rev, reverse primer). 
Primer Sequence (5`-3`) 
A68W-FW 5`-GGC CGG GCT GTT CCC TGC GAG CC-3` 
R199W-FW 5`-GCC CTT GGT TTG GAC AGA CAA CC-3` 
R199W-Rev 5`-GGT TGT CTG TCC AAA CCA AGG GC-3` 
T349I-FW 5`-CAC CAT TTA CCA GCC TCT CTC GGG-3` 
S533N-Rev 5`-GAC CCA GGT GTT CAT GGC GAT GC-3` 
K575M-FW  5`-CTT CTC TAT GCG GCA CGA GC-3` 
K575M-Rev 5`-GCT CGT GCC GCA TAG AGA AG-3` 
P755F-Rev 5`-CAT GCC ACG AAG GCC GGT GCA CT-3` 
pEF.6 29U31 5`-CTG TGT TCA CTA GAA TTC TCA AAC AGA CAC C-3` 
pEF.6 202L18 5`-GTG ATA CTT GTG GGC CAG-3` 
 
(See protocol description 8.2.1). 
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3.2.1 Agarose gel electrophoresis 
Agarose gel electrophoresis was performed to identify and separate DNA fragments of 
different sizes. Agarose dissolves upon heating to ≤ 90˚C and forms a gel by polymerisation 
upon cooling. Small DNA fragments of 0.1-2 kilobases may be separated by 1.0-1.3 % 
agarose gels, whilst larger fragments 2-10 kb are separated by 0.6-1.0% agarose gels. The 
DNA molecule`s negatively charged phosphate groups make the DNA molecules migrate 
through the agarose gel towards the cathode in an electrical field. To determine the size of 
the separated DNA molecules, the DNA bands were compared to DNA marker fragments of 
known sizes run on the same gel. The gel was preloaded with ethidium bromide, which binds 
between the basepairs of the DNA double helix, and makes the fragments visible under UV-
light.  
Agarose gel electrophoresis was used to identify and isolate the PCR-products, and to 
separate and purify restriction products for ligation reaction. 
(See protocol description 8.2.2). 
3.2.2 Extraction of DNA from agarose gels 
Isolation and purification of DNA fragments from agarose gels was performed using 
QIAquick Gel Extraction kit (QIAGEN). First, the agarose gel was solubilised in the 
presence of a chaotropic salt (NaClO4) which breaks the hydrogen bonds in the agarose. The 
solution was then filtered through a silica membrane, which binds DNA at high salt 
concentration. The silica membranes with bound DNA were washed with the Buffer PE, an 
ethanol containing solution, to remove contaminants. Any residual Buffer PE was removed 
by an additional centrifugation step. The pure DNA was eluted with EB Buffer, a buffer with 
low salt concentration.  
(See protocol description 8.2.3). 
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3.3 PLASMID PROPAGATION 
Eukaryotic DNA plasmids transformed into bacteria are replicated independently of the host 
genome. Thus transformed bacteria can be used to produce plasmids copies at large scale, 
which in turn can be used in transfection of cell lines (i.e. NIH/3T3). 
Strains of Escherichia coli (E. coli) were used for transformation. These bacteria have been 
pre-treated with various chemicals to become competent for DNA transformation. “TOP-10 
Chemically Competent E.coli” from Invitrogen was used in this thesis. The transformed 
bacteria were grown on selective medium plates (Luria Bertani (LB) medium with agar 
containing antibiotic ampicillin 80 μg/ml). The pEF.6 Smo wt vector and p3xFLAG-CMV-
10 vector contains an ampicillin resistance encoding gene, and only the bacteria transformed 
with vectors would survive in the presence of ampicillin. The plasmid DNA was isolated 
using either small-scale (Wizard® Plus SV Miniprep Kit, Promega) or large-scale (HiSpeed 
Plasmid Maxi Kit, QIAGEN) plasmid preparations. Both kits were used for amplification of 
these constructs: 
o p3xFLAG-CMV-10 Smoothened wild type  
o p3xFLAG-CMV-10 R484W-Smo  
o p3xFLAG-CMV-10 L514F-Smo  
o p3xFLAG-CMV-10 S533N-Smo  
o p3xFLAG-CMV-10 W535L-Smo  
o p3xFLAG-CMV-10 K575M-Smo  
o pEF.6 K575M-Smo 
3.3.1 Vectors 
The pEF.6 vector 
K575M-Smo encoding cDNA was inserted into the pEF.6 
vector (pEF.6 Smo wt; Figure 3.2). The other Smo-mutation 
constructs were available in the laboratory, already inserted to 
the pEF.6 vector. The pEF.6 vector was a kind gift from 
Professor Richard Marais laboratory, Institute of Cancer 
Research, London UK.  Figure 3.2: pEF.6 Smo wt 
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The p3xFLAG-CMV-10 vector 
Complimentary DNA (cDNA) encoding R484W-, L514F-, S533N-, W535L-, K575M-Smo 
and Smo wt has been inserted into the p3xFLAG-CMV-10 vector (Sigma) (Figure 3.3), after 
generating restriction sites enabling direct ligation. The p3xFLAG-CMV-10 vector is a 6.3 
kb vector derived from pCMV5. The vector encodes three adjacent FLAG-epitopes that 
results in increased detection sensitivity using anti-FLAG M2 antibody.  It also contains the 
aminoglycoside phosphotransferase II gene (Neo), which confers resistance to 
aminoglycosides such as G-418. This allows for selection of stably transfected cells. 
 
Figure 3.3: p3xFLAG-CMV-10 expression vector (Adopted from Sigma-Aldrich, Inc. Product Information). 
3.3.2 Transformation 
The DNA was forced into the “TOP10” competent E.coli bacteria (Invitrogen) by incubating 
the cells and the DNA together on ice, placing them briefly at 42oC (heat shock), and then 
putting them back on ice according to the protpcol description 8.2.4. This presumably caused 
the bacteria to take in the DNA. The cells were then plated out on ampicillin containing LB 
agar plates, selecting the bacteria cells with incorporated plasmid containing ampicillin-
resistent gene [74].  
(See protocol description 8.2.4) 
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3.3.3 Small-scale plasmid preparation 
The Wizard Plus SV Minipreps DNA Purification System kit (Promega) was used for small-
scale isolation and purification of plasmid DNA from transfected E. coli hosts. This system 
provides a simple and rapid isolation of plasmid DNA using a solid-phase silica-impregnated 
filter membrane. The procedure includes bacterial cell disruption and lysis using a solution 
containing NaOH and SDS. The chromosomal DNA, cell membrane components and 
denatured proteins precipitate upon neutralisation and increasing salt concentration. Plasmid 
DNA remains intact in the solution, but endonucleases and proteins are degraded when 
adding an alkaline protease solution. A silica-based membrane binds the plasmid DNA when 
running the plasmid lysate through using a microcentrifuge. The binding is accomplished 
due to interaction between the positively charged groups at silica-membrane and the 
negatively charged backbone of DNA molecules. The membrane is washed with an ethanol 
containing buffer with high salt concentration to remove residual contaminants. Finally, the 
plasmid DNA is eluted in nuclease-free water. Purified plasmids were sent for DNA-
sequencing (protocol description 8.2.9).  
(See protocol description 8.2.5). 
3.3.4 Quantification of DNA  
Spectrophotometrical quantification of plasmid DNA was used to determine nucleic acid 
concentrations. Quantification was performed by measuring optical absorption at λ = 230 
nm, 260 nm and 280 nm (OD230, OD260 and OD280). These wavelengths were selected based 
on the UV-light absorption of nucleotides (200-300 nm), amino acids, urea and phenol (190-
280 nm). All nucleotides have a λmax near 260 nm which is specific for the purine and 
pyrimidine bases thus absorption at this particular wavelength can give an estimate of the 
DNA concentration in a sample. Measuring absorption at 230 nm and 280 nm indicate 
possible impurities (e.g. urea, proteins and phenols, but not RNA). Contamination by RNA 
can not be detected by UV analysis as both RNA and DNA have absorption maxima at about 
260 nm. The ratio OD260/ OD280 and OD260/ OD230 estimates DNA purity, where values 
between 1.8-1.9 and 1.8-2.2, respectively, are acceptable. The total amount of DNA can be 
calculated using the formula: 
[DNA] (μg/μl) = OD260 x dilution/20 
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The spectrophotometer Ultrospec 2100 UV pro UV/Visible from Amersham Pharmacia 
Biotec was used when quantifying DNA.  
(See protocol description 8.2.6). 
3.4 SUB-CLONING 
The term sub-cloning is used for the process of moving a DNA-insert from one vector to 
another. The method involves restriction enzyme digestion, agarose gel electrophoresis, 
isolation of the DNA-fragments and finally ligation. The method was used to move the 
desired coding region of wild type and the five mutated versions of Smo from the pEF.6 
vector to the p3xFLAG-CMV-10 vector. 
Before inserting the mutants in the desired vector, an EcoRI restriction site had to be 
generated adjacent to the ATG start codon of the various Smo constructs. This was done 
with PCR-reaction as described in section 3.2 (protocol description 8.2.1 step 2), where the 
forward primer contains a mismatch resulting in an EcoRI restriction site in the PCR-
product. Subsequently the vectors and inserts were digested with EcoRI and XbaI restriction 
enzymes and separated by gel electrophoresis. Finally, the purified digestion products were 
ligated using T4 DNA ligase.  
(See protocol description 8.2.7). 
3.4.1 Large-scale plasmid preparation  
To produce larger amounts of purified plasmid-DNA, large-scale plasmid preparation was 
set up using the QIAGEN Hispeed Plasmid Maxi Kit. First, bacteria culture was prepared 
and incubated in a shaking incubator overnight, and then centifugated the next day, 
precipitating the bacteria. Secondly, the bacteria containing desired plasmid DNA were 
resuspend in presence of RNase A (buffer P1), and then lysed using a NaOH and SDS 
containing solution (Buffer P2). SDS solubilises phospholipids and proteins, NaOH 
denatures chromosomal and plasmid DNA, while RNase A digests liberated RNA. Addition 
of acidic potassium acetate (Buffer P3) neutralizes the lysis and causes potassium dodecyl 
sulphate (KDS) to precipitate. The cell residue becomes trapped in salt-detergent complexes, 
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while plasmid DNA remains in the solution because of its smaller size. The lysate was 
cleared through a QIAfilter Cartridge and loaded on a QIAGEN anion-exchange resin. The 
resin consists of silica beads with a defined particle size and a hydrophilized surface coated 
with diethylaminoethyl (DEAE). Under low salt and pH conditions, DNA is bound to the 
resin through interaction between their negatively charged phosphate backbone and the 
positively charged groups of DEAE. A medium-salt buffer (Buffer QC) removes any 
remaining contaminants, such as RNA traces and proteins. The plasmid DNA was efficiently 
eluated with high-salt buffer (Buffer QF) and the purified plasmid DNA was used in 
transfection and other experimental procedures.  
 (See protocol description 8.2.8). 
3.5 CELL TREATMENTS 
3.5.1 NIH/3T3-cells and 293 EcR Shh cells 
The following methods were all carried out with the 
mouse embryonic fibroblast cell line, NIH/3T3-cells 
obtained from American Type Culture Collection 
(ATCC) (Figure 3.4). NIH/3T3-cells adhere to plastic 
surfaces and grow in newborn calf serum (NCS). 
Under optimal growth conditions (37°C, 5% CO2 in 
air), the cells double about every 36 hours. The cells 
were subcultured twice per week at 80% confluency 
or less. (Complete growth medium: DMEM (4.5 g glucose/L) supplemented with 5% NCS. 
For the stably transfected cells 0.4 mg/ml G-418 was added to the growth medium). 
293 EcR Shh cells are epithelial kidney cells also obtained from ATCC. 293 EcR Shh cells 
are transformed with one arm of the adenovirus 5 DNA created in 1998 by stably 
transfecting HEK293 cells with the Ecdysone-Inducible Mammalian Expression System 
(Invitrogen). 293 EcR Shh cells carry a construct for the expression of murine Sonic 
hedgehog (Shh) under control of an Ecdysone-inducible promoter. The cells were used for 
production of biologically active murine Shh secreted in the medium. Ponasterone A is an 
Figure 3.4: NIH/3T3-cells growing 
in culture (Olympus IX81, 40x). 
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analogue of Ecdysone and was used to induce production of Shh. Under optimal growth 
conditions (37°C, 5% CO2 in air), the cells double about every 23 hours. (Complete growth 
medium: DMEM (4.5 g glucose/L) supplemented with 10% FBS, fetal bovine serum. 
Antibiotics used: 0.4 mg/ml G-418 and 0.4 mg/ml Zeocin).  
3.5.2 Thawing cells 
The NIH/3T3-cells and EcR 293 Shh cells were stored frozen in the liquid nitrogen tissue 
culture library tank. These cells were thawed according to protocol 8.2.10. 
(See protocol description 8.2.10) 
3.5.3 Splitting cells 
NIH/3T3 cell cultures grow as a monolayer attached to the bottom of the plastic culture dish. 
The cells were cultured until they were 70-80% confluent before splitting at a ratio of 1:3 to 
1:12. At higher densities, the cells may form a very dense monolayer, which is difficult to 
split. At 70-80% confluency the NIH/3T3-cells were treated with trypsin-EDTA. Trypsin is 
a proteolytic enzyme and EDTA is a calcium chelator. The cells were detached from the 
culture dish surface when adding trypsin-EDTA, and the cells were subcultured onto new 
dishes after centrifugation and resuspension.  
 
293 EcR Shh cells showed a tendency to grow in clusters, and were cultured until 50-70% 
confluence. The cells were subcultured at a ratio of 1:4 to 1:10, and medium were changed 
two to three times weekly. 293 EcR Shh cells were used to generate conditioned medium 
used to stimulate the Hedgehog-signal pathway in NIH/3T3-cells. Conditioned medium was 
prepared by plating 1x106 cells in 100 mm dishes. The next day the growth medium was 
changed and the cells were cultured in the presence of Ponasterone A (5 μM) for 24h to 
induce expression of Shh. Ponasterone A is an analog of Ecdysone, an insect steroid that 
regulates the metamorphosis of Drosophila melanogaster. 
(See protocol description 8.2.11) 
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3.5.3.1 Counting cells 
Cell counting was performed when setting up experiments like RT-PCR, gene reporter 
assay, and when generating conditioned media. The cells were counted when it was 
desirable to achieve confluencity at the same point of time. Countess Automated Cell 
Counter from Invitrogen was used according to protocol description 8.2.11.1. 
(See protocol description 8.2.11.1) 
3.5.4 Freezing cells 
When cells freeze, their plasmamembranes disrupt and vital parts are damaged due to ice 
crystal formation. The use of cryoprotective medium containing 15% DMSO prevents cell 
rupture. A slow cooling and freezing process, reducing the sample temperature 
approximately 1˚C per hour, increases survival of the cells, but the process should not be too 
slow due to the toxicity of DMSO present in the cryoprotective medium. Freezing cells was 
performed according to protocol 8.2.12. 
(See protocol description 8.2.12). 
3.6 CELL BASED EXPERIMENTS 
3.6.1 Transfecting cells 
Transfecion is a method used for introduction of biomolecules like DNA, RNA or proteins 
into eukaryotic cells. This can be achieved by different techniques, but for NIH/3T3-cells the 
method employing Lipofectamine 2000 is widely used and works well. This is a cationic 
lipid based method giving transfection rates of up to 60%. Lipofectamine 2000 is a 3:1 
(w/w) liposome formulation of positively charged liposomes, which interact with the 
negatively charged phosphate groups of the nucleic acid and forms a complex. These 
complexes enable hydrophilic DNA to cross the hydrophobic plasma membrane of the cells 
by endocytosis. Inside the cell the plasmids can be replicated and transcribed episomally. 
Transfection of cells was performed according to protocol 8.2.13. 
(See protocol description 8.2.13). 
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3.6.2 Generation of monoclonal cell lines 
Monoclonal cell lines were generated according to protocol 8.2.14. 
(See protocol description 8.2.14) 
3.6.3 Transfection for reporter gene assay (transient transfection) 
Luciferase-assay was used to address the signalling properties of the mutated and wt 
versions of Smo expressed in monoclonal cell lines. The different cell lines were seeded in 
separate columns in a 96-well plate, and subsequently transfected with the Gli-BS-Luc- and 
Renilla-Luciferase constructs according to protocol 8.2.15. Fore more details about the 
Luciferase-assay method see section 3.7.1. 
(See protocol description 8.2.15). 
3.6.4 Stimulation and harvesting of cells for gene reporter assay 
To analyse activation of Gli-reporter in transfected NIH/3T3-cells, the half of the cells were 
serum-starved in 0.5% NCS-DMEM, and the other half were treated with Shh-conditioned 
medium produced by the 293 EcR Shh cells. The Gli-reporter in stimulated cells should be 
more activated than in the starved cells, because Shh increases the Hedgehog signalling 
pathway activity, and thereby Gli transcription factor activity. See section 3.7.1 for more 
information about the Luciferase-assay method. 
(See protocol description 8.2.16). 
3.7 ANALYSIS OF CELL EXPERIMENTS 
3.7.1 Gene reporter assay: Luciferase assay 
Methodological principle 
Luciferase-assay is a genetic reporter system used to analyse eukaryotic gene expression and 
cellular physiology. The assay contains firefly luciferase protein which catalyzes luciferin 
oxidation and generate light in the reaction. In this study we have used the firefly luciferase 
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protein as a report gene analysing the Gli1 activity in stably transfected NIH/3T3-cells. In 
this method there are two individual reporter enzymes within a single cell, where the 
experimental reporter is correlated with the effect of specific experimental conditions. The 
activity of the control reporter provides an internal control and serves as the baseline 
response. Experimental variability caused by differences in cell viability or transfection 
efficency is, in theory, minimised when normalising the activity of the experimental reporter 
to that of the internal control [75]. 
Before running Luciferase-assay, transfection of the NIH/3T3-cells was preformed. The 
constructs to be transfected are the Gli BS-Luc (Gli-binding sequence-luciferase) 
experimental reporter construct, and Renilla-luciferase construct (internal control). The Gli 
BS-Luc construct expresses Luciferase under control of the Gli1-dependent promoter. 
Increased Gli1 activity is a result of activated hedgehog signalling pathway. The cells were 
lysed with Passive Lysis Buffer prior to reagent addition. The Gli BS-Luc reporter activity 
was measured first by adding Luciferase Assay Reagent II (LAR II) to generate a 
luminescent signal lasting at least one minute. After quantifying this signal, this reaction was 
quenched, and the Renilla luciferase reaction was initiated simultaneously by adding Stop & 
Glo reagent to the same sample. Dual-Luciferase® Reporter 1000 Assay System (Promega) 
was used according to the protocol description 8.2.17. 
(See protocol description 8.2.17). 
3.7.2 Gene expression analysis by quantitative polymerase chain reaction  
Methodological principle 
Quantitative analysis of mRNA expression was performed using real-time reverse 
transcription polymerase chain reaction (real-time RT-PCR), which is a highly sensitive 
technique used for mRNA detection and quantification [76]. Total RNA was isolated from 
NIH/3T3-cells, purified and transcribed into complementary DNA (cDNA) by SuperScript 
III reverse transcriptase. DNA polymerase and specific primers amplifies the new-formed 
cDNA, and the PCR-products were measured continuously during the amplification step. 
Subsequently, calculation of the original level of mRNA in the sample was performed. 
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In this study, the mRNA expression levels of human Smo (hSmo), mouse Gli1 (mGli1) and 
mouse Ptch (mPtch) in stably transfected NIH/3T3-cells was measured by real time RT-
PCR. 
3.7.2.1  Isolation of RNA 
A critical step when isolating nucleic acids is to separate nucleic acids from proteins. This is 
accomplished due to their different chemical properties. Nucleic acids are hydrophilic 
compared to the more hydrophobic proteins due to the highly charged phosphate backbone. 
RNeasy Mini Kit from QIAGEN was used to isolate total RNA. The protocol contains a 
DNase treatment step, where all RNA samples were treated with deoxyribonuclease 
(DNase). The DNase digests every strand of DNA present. To avoid introducing exogenous 
ribonuclease (RNase) to the samples, gloves were worn at all times and changed frequently. 
All reagents and equipment used were RNase free and decontaminated with RNase-OFF 
routinely. 
 
(See protocol description 8.2.18). 
3.7.2.2 Determination of RNA purity, quality and concentration 
The RNA quality was assessed both by spectrophotometry and gel electrophoresis. The 
concentration and purity of RNA in the samples was determined by measuring the 
absorbance at 260 nm (A260). The ratio between the absorbance at 260 nm and 280 nm (A280) 
gives an estimate of the RNA purity concerning protein contaminations. The NanoDrop ND-
1000 (NanoDrop Technologies) spectrophotometer was used, which is a full-spectrum (220-
750 nm) spectrophotometer measuring sample volumes down to 1 µl with high accuracy and 
reproducibility. Two µl samples were positioned on the electrodes. The electrodes were 
wiped clean between every measurement when measuring multiple samples. RNase-free 
water was used as a blank.  
To verify the RNA quality, 1 µg of the total RNA preparations were fixed in formamide and 
subjected to agarose gel electrophoresis (1% agarose gel preloaded with ethidium bromide)  
to separate the 28S and 18S rRNA fragments. RNA moves towards the positive pole in an 
electrical field because it is negatively charged at neutral pH. The 18S and 28S bands of 
RNA in the gel are stained with ethidium bromide. The bands are visualized under ultra 
violet (UV) light, and are visible when the RNA is of high quality (Figure 3.5). 
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Figure 3.5: Agarose (1%) gel electrophoresis of a representative selection of total RNA samples. The RNA 
integrity was evaluated by inspection of the 28 S and 18 S rRNA bands The RNA was of high quality and 
showed only minor degradation of the total RNA samples. 
(See protocol description 8.2.19). 
3.7.2.3 First strand cDNA synthesis 
Single stranded mRNA is too unstable to serve as a template for PCR therefore single 
stranded mRNA was transcribed into cDNA (complementary DNA). This was accomplished 
by the use of the SuperScript III (SSIII) reverse transcriptase (RT) (Invitrogen) which is a 
RNA-dependent DNA polymerase. Based on spectrophotometric concentration 
determinations 2.5 μg total RNA was mixed together with oligo dT primers, a dNTP mix 
(equal amount of dATP, dGTP, dCTP and dTTP, all Invitrogen), and RNase-free water to a 
volume of 13 μl. The mixture was heated to 65ºC allowing the primers to anneal. SSIII, 
RNaseOut, First-Strand Buffer and DTT were added to a total volume of 20 µl. To 
synthesise cDNA the following temperature-program was used: 
25 ˚C 5 minutes 
50 ˚C 60 minutes 
70 ˚C 15 minutes (Inactivate the reaction) 
4 ˚C End 
Reactions were also carried out without reverse transcriptase (-RT) as a negative control. 
These control samples were used to determine whether there were traces of genomic DNA in 
the prepared RNA samples. In these reactions SuperScript III RT and RnaseOut was 
replaced by DNase-free water.  
 
(See protocol description 8.2.20). 
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3.7.2.4 RT-PCR 
Quantitative real-time RT-PCR (qPCR/RT-PCR) was used to amplify and simultaneously 
quantify a specific sequence in a DNA molecule (amplicon). Quantification was 
accomplished by registration of a reporter conjugated to the amplicon that accumulates at the 
same rate. Both SYBRgreen and Taqman probe was used in this study as labelling reagents, 
and allow detection of PCR-products via generation of a fluorescent signal. In this study, 
SYBRgreen technology was used to quantify the genes of interest including hSmo, mGli and 
mPtch and the housekeeping control gene TATA box binding-protein (Tb-p) (see below). 
The primer and probe technology (Taqman probe) was used for quantification of the 
housekeeping control gene glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) (see 
below). 
SYBRgreen is a dye that binds to the minor groove of the nascent double-stranded DNA 
during elongation. The resulting DNA-dye-complex sends a fluorescent signal during the 
polymerisation step. The main drawback of this method is that SYBRgreen binds to any 
double-stranded DNA present which may lead to an overestimation of the target 
concentration. Specific primer pairs secure high specificity when using the SYBRgreen 
technology. The specificity of the RT-PCR products was verified by melting-point analysis 
[76]. 
Primer and probe-based RT-PCR distinguishes between specific and non-specific 
amplification. The TaqMan probe is a short single stranded oligonucleotide sequence that is 
complementary to one of the DNA strands in the amplicon. A fluorophore-reporter is 
attached to the 5`-end of the probe and a quencher to the 3`-end.  While the probe is intact, 
the closeness of the quencher will reduce the fluorescent signal sent out by the reporter due 
to fluoroscence resonance energy transfer (FRET). The reporter transfers the energy to the 
quencher, which releases the energy as light of a higher wavelength which is not being 
detected. The DNA polymerase displays a 5`-3`nuclease activity, and will therefore 
hydrolyse an oligonucleotide bound to its target sequence. Based on this the reporter is 
separated from the quencher during the synthesising process and FRET will no longer occur 
when the reporter and quencher are separated. This leads to an increase in fluorescence 
proportional to the accumulation of amplicon which the real-time quantitative RT-PCR 
machine will detect [76].  
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The cycle threshold (Ct) value is defined as the cycle number at which the fluorescence is 
higher than the baseline fluorescence. The higher the starting copy number of the nucleic 
acid target, the sooner this is reached [77]. 
A standard curve with increasing concentrations of RNA is run in parallel to ensure a 
representative transcription of mRNA into cDNA for reliable quantification. A pooled 
reference sample is made from the RNA-samples, which is coamplified with the 
experimental sample during cDNA-synthesis. A standard curve for quantification of 
amplification of the amplicon was generated. The standard curve is an important control of 
reverse transcription of mRNA into cDNA. 
Two housekeeping genes were used to normalise the expression of the template for sample-
to-sample variations in RT-PCR efficiency and for errors in sample quantification. Ideally, 
the housekeeping genes should not be affected by the experimental conditions, and should 
have minimal variations in expression among different tissues of an organism, at all stages of 
development.  In this study, mRNA for glyceraldehyde-3-phosphate-dehydrogenase 
(GAPDH) and TATA box binding-protein (Tb-p) were used as internal standards.  
Figure 3.6 shows an example of measured hSmo expression level in one RT-PCR 
experiment analysed relative to both GAPDH (Figure 3.6 A) and Tb-p (Figure 3.6 B). Both 
normalisation genes gave approximately the same pattern of hSmo expression level in the 
various monoclonal cell lines.  
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Figure 3.6: Human Smo mRNA expression level relative to GAPDH (A) and Tb-p (B).  
The real time RT-PCR assays (15μl) were run in a 384-well temperature block operated by 
an ABI Prism 7900HT Sequence Detection System (Applied Biosystems). 
(See protocol description 8.2.21). 
3.7.2.5  Primer and probe design 
The primers and probes used in this study were available in the laboratory (Table 3.2 and 
3.3). To get an effective amplification of the target sequence and reliable quantification, it is 
very important to design specific primers and probes. Using specific primers and probes 
avoids unreliable signals from primer dimers, primer-probe dimers and replication of other 
genes due to unspecific bindings.  
 Receptor/Gene Gene ID 
(PubMed) 
Primer Sequence (5`-3`) 
hSmo 6608 Forward #499 
Reverse #500 
5`-GGA CTA TGT GCT ATG TCA GG-3` 
5`-AGG TTG ATC TTC TCC ACC AG-3` 
mGli1 14632 Forward #507 
Reverse #508 
5`-CTG TCG GAA GTC CTA TTC AC-3` 
5`-ACG TAT GGC TTC TCA TTG GA-3` 
mPtch 19206 Forward #503 
Reverse #504 
5`-CTG TAA CAA CTA TAC GAG CCT G-3` 
5`-AGG ACC ATG ACA ATG ATC CC-3` 
Table 3.2: Oligonucleotide sequences of the primers used for real-time RT-PCR. 
43 
Normalization 
gene 
Gene ID 
(PubMed) 
Primer/ 
Probe 
Sequence (5`-3`) Repor-
ter dye 
Quencher 
dye 
GAPDH 10190788 Forward 
Reverse 
Probe 
5`-CCA AGG TCA TCC ATG ACA ACT T-3` 
5`-AGG GGC CAT CCA CAG TCT T-3` 
5`-CTC ATG ACC ACA GTC CAT GCC ATC 
ACT-3` 
 
 
Yakima 
Yellow 
 
 
Dark 
Quencher 
Tb-p 51948367 Forward 
#454 
Reverse 
#455 
5`-ATCTTGGCTGTAAACTTGAC-3` 
 
5`-GGATTGTTCTTCACTCTTGG-3` 
  
Table 3.3: Oligonucleotide sequences of the primers and probes for normalization genes used in real time RT-
PCR. 
3.7.2.6 Calculations 
Analysis of quantitative RT-PCR data 
An amplification plot was generated from every sample by using Sequence Detector 
Software (SDS version 2.2, Applied Biosystems). The amplification plot shows the increase 
in the reporter dye fluorescence with each PCR cycle. Ct values from each amplification 
cycle were automatically calculated, and it represents the PCR cycle number at which the 
fluorescence is first detected above the baseline. The Ct values were then exported into 
Microsoft Excel for further calculations.  
Standard curves for each set of primer/probe set were made by plotting Ct values versus log 
initial amount of RNA for the different standard dilutions, giving a straight line (Equation 1). 
The slope describes the efficiency of the PCR. If the PCR amplification is optimal, the slope 
will be -3.3, as 3.3 cycles are required to generate a 10-fold increase in product amount. 
Ct= a (log Q) + b           (1) 
Ct is the threshold cycle, a is the slope, Q is the initial copy number and b is the intercept on 
the y-axis. 
Equation 1 can easily be rearranged to: 
log Q = Ct – b                 (2) 
                 a  
The initial amount of target RNA can be calculated using this equation. The slope a and 
intercept b is calculated from the standard curve and the obtained Ct values for the different 
samples. 
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The expression of hSmo, mGli1 and mPtch mRNA were normalized to the expression level 
of the reference gene GAPDH across all samples and some values were also normalized to 
the expression level of the Tb-p reference gene. Each sample was run in triplicates, and the 
mean values of the triplicates were used to calculate the ratio between the different genes 
and the normalization gene. The data were transferred into Microsoft Excel and GraphPad 
Prism5 Software (Prism) for graphical presentation. The data in GraphPad were expressed as 
mean ± SEM from n experiments, and the data in Excel were expressed as mean ± SD from 
n experiments. 
3.7.3 Protein concentration determination 
Methodological principle 
BCA (bicinchoninic acid) Assay protein quantitaion kit (BCAssay: 
protein quantitation kit, Uptima) was used to determinate the 
protein concentration in cell lysate samples, and this is a 
colorimetric assay based on the Biuret reaction. Proteins reduce 
Cu2+ in alkaline solutions to Cu+, and reduced Cu+ interacts with 
two molecules of bicinchoninic molecules and forms a water-
soluble purple coloured complex with an absorption maximum 
of 562 nm (figure 3.7). The absorption is proportional to the initial protein concentration. 
The protein concentrations were recorded using a microplate reader-Multiscan EX (Thermo 
Electron Corporation) or an EnVision 2104 Multilabel Reader (Perkin Elmer precisely). 
(See protocol description 8.2.22). 
3.7.4 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) 
Methodological principle 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is an 
electrophoresis method used to separate proteins of various sizes in an electric field. 
Polyacrylamide is a polymer of acrylamide monomers that forms a dense porous gel when it 
polymerises. SDS is a strong anionic detergent which has a hydrophobic tail that interacts 
Figure 3.7: Bicinchoninic acid 
interacting with Cu+. 
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strongly with polypeptide chains, giving them a negative charge. SDS also disrupts the 
bonds that make up the three dimensional conformation of proteins. β-mercaptoethanol is a 
reducing agent and was added to disrupt disulfide bridges in the polypeptide. Disulfide 
bridges can influence the migration of the proteins. The samples were boiled at 95˚C for 5 
minutes to facilitate the denaturation process. The denaturated polypeptides obtained a linear 
structure covered with negatively charged SDS. The protein migration through the 
polyacrylamide gel are only depended on the size of the proteins, because SDS-denatured 
polypeptides have an approximately uniform mass:charge ratio. The negatively charged 
polypeptides migrate towards the positive pole.  
(See protocol description 8.2.23). 
3.7.5 Western blotting 
Methodological principle 
After electrophoresis the proteins in the gel were subjected to electroblotting. The proteins 
were negatively charged by the bound SDS, and were readily transferred to a PVDF 
membrane (or nitrocellulose membrane when using Odyssey Infrared Imaging System, LI-
COR Biosciences, see below) in an electrical field. For this procedure, an electric current 
was applied to the gel so that the separated proteins moved through the gel and onto the 
membrane while maintaining their relative position as they were separated by the SDS-
PAGE. All sites on the membrane which do not contain transferred proteins from the gel 
were then “blocked” so that antibodies used for detection of the target protein did not bind 
non-specifically to the membrane. Non-specific binding of antibodies to membrane causes a 
high background signal. “Blocking” of the membrane was achieved by placing the 
membrane in a non-fat dry milk protein solution dilute in phosphate buffer saline 
(PBS)/0.5% Tween 20. 
After blocking, a primary antibody was added in an appropriate dilution to detect a specific 
protein (antigen) blotted on the membrane. The antibody-dilution was incubated with the 
membrane overnight. The next day, the membrane is rinsed and subsequently incubated with 
a secondary antibody. Horseradish peroxidises (HRP)-linked secondary antibody was added 
to PVDF membranes, and Infrared (IR)-Dye linked secondary antibody was added to 
nitrocellulose membrane when using Odyssey. The secondary antibody binds to the Fc 
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portion of primary antibodies. In order to detect the specific protein-antibody interactions 
when using HRP-linked secondary antibody, a chemiluminescence substrate containing 
luminol was added to the conjugate. Upon reaction with the conjugate, HRP catalyses the 
breakdown of luminol thus emitting light and resulting in a visible band where the primary 
antibody has bound to the protein, when detected with an EpiChemi II Darkroom-camera 
(UVP Laboratory Products). The IRDye-linked secondary antibody did not need to be 
activated when using Odyssey. The Odyssey Infrared Imaging System detected the specific 
protein-antibody interactions by measuring the infrared light from the IRDye-linked 
secondary antibody. The intensity of the signal correlated with the abundance of the antigen 
on the blotting membrane. 
(See protocol description 8.2.24).  
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4. RESULTS 
This thesis is part of an ongoing project investigating the importance of somatic mutations in 
Smo on Smo-mediated signalling. Smo is part of the Hh signalling pathway, and currently 
fourteen somatic mutations have been identified in Smo and are registered in the Catalogue 
Of Somatic Mutations in Cancer (COSMIC) database. In this thesis five of the fourteen 
mutations were studied, in addition to Smo wild type (wt) and the p3xFLAG-CMV-10 
empty vector (control). One of the mutants, K575M-Smo, was generated in the laboratory as 
part of this thesis work. 
4.1 MUTAGENESIS, K575M-SMO, IN SMO WT 
The K575M-Smo was generated by two polymerase chain reactions (PCR) as described in 
the Methods chapter. Two products with the desired mutation were generated in the first set 
of reactions (PCR-I), using pEF.6 Smo wt as template and two sets of primer pairs (A 
R199W-Forward (FW) and K575M-Reverse (Rev), B K575M-FW and P755F-Rev; Table 
3.1). The PCR-product sizes determined by agarose gel electrophoresis corresponded to the 
theoretical fragment sizes of 1151 bp and 558 bp, respectively (Figure 4.1).  
 
In the second set of PCR-reactions (PCR-II) the two products from PCR-I served as 
templates, and the flanking primers from PCR-I (R199W-FW and P755F-Rev) were used to 
initiate DNA synthesis. The theoretical size of this product was 1689bp. The polymerase 
chain reaction gave linear double-stranded DNA containing the K575M Smo-mutation. This 
product was not separated on agarose gel, but was purified directly with QIAquick Gel 
Extraction Kit and subsequently digested with the restriction enzymes Tth111I and SphI. 
Figure 4.1: Agarose (1%) gel of Smo PCR-
products from PCR-I. pEF.6 Smo wt served 
as template in both PCR-I reactions with the 
primer pairs R199W-FW and K575M-Rev 
(lane A, expected product size 1151 bp) and 
K575M-FW and P755F-Rev (lane B, expected 
product size 558 bp). The 1 kb Plus DNA 
ladder was used as molecular size marker (left 
lane).
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4.1.1 Restriction enzyme digestion and ligation of K575M-Smo and pEF.6 
vector  
The PCR-II-product containing the mutant K575M-Smo mutation and pEF.6 Smo wt 
plasmid were digested with the restriction enzymes Tth111I and SphI. Digestion of the PCR-
II-product, K575M-Smo, should theoretically generate DNA fragments of 359 bp, 520 bp, 
and 840 bp. The pEF.6 Smo wt vector was digested into fragments of sizes 840 bp (Smo wt) 
and 6337 bp (pEF.6 vector; Figure 4.2). The fragment of 840 bp from K575M-Smo and the 
pEF.6 vector fragment of 6337 bp were isolated from the gel and purified.  
  
After purification, digested K575M-Smo was ligated into the equally cut pEF.6 vector by T4 
DNA ligase (Figure 4.3). The resulting plasmid was transformed into “TOP10” competent E. 
coli bacteria.  
 
Figure 4.2: Agarose (1%) gel electrophoresis 
of restriction enzyme fragments of the PCR-II-
product K575M-Smo and pEF.6 Smo wt 
vector digested with Tth111I and SphI. The 
840 bp product from K575M-Smo (lane A), and 
the 6337 bp product of the pEF.6 Smo wt plasmid 
(lane B) were isolated from the gel and purified. 
The 1 kb Plus DNA ladder was used as molecular 
size marker (left lane).
Figure 4.3: pEF.6 vector. The 
PCR-II-product of the K575M-
Smo mutation was inserted into 
the pEF.6 vector in the Tth111I 
and SphI restriction sites as 
indicated. The pEF.6 vector was a 
kind gift from Professor Richard 
Marais, Institute of Cancer 
Research, London UK. 
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4.1.2 The sequence of pEF.6 K575M-Smo wt was verified by DNA-
sequencing and agarose gel electrophoresis  
The pEF.6 vector contained an ampicillin resistance encoding gene, therefore only the 
bacteria that were transformed with these vectors survived in the presence of ampicillin in 
LB agar plates. Ten colonies of bacteria were selected and grown in culture tubes but only 
nine grew in the presence of ampicillin. The plasmid DNA in the bacteria was isolated in 
small scale. After isolation, the nine plasmid DNA presumably containing the pEF.6 
K575M-Smo plasmid were sent for DNA-sequencing and analysed by agarose gel 
electrophoresis (Figure 4.4). The plasmids were uncut and circular, and could therefore not 
directly be compared with the linear DNA-fragments of the molecular size marker applied in 
the left lane. Plink (polylinker, a pEF.6 empty vector) was run as control and was of smaller 
fragment than pEF.6 K575M-Smo plasmids, which indicate that the plasmids contained the 
expected inserts. The pEF.6 Smo wt was also run as control, and was of approximately same 
size as the pEF.6 K575M-Smo plasmids, indicating that the plasmids contained the expected 
inserts. The R199W-FW and T640A-Rev primers were used for sequencing, giving a 
nucleotide sequence of approximately 1300 bp in the middle of the Smo wt cDNA sequence 
containing the mutation K575M. The DNA sequences from the sequencing-lab were 
analysed (not shown in this thesis), and five of the nine sequenced constructs (Figure 4.4 
lane 2, 3, 4, 7 and 9) showed the intended K575M-Smo mutation and no additional PCR-
introduced mutations. One of the five plasmids (Figure 4.4 lane 2) containing the K575M 
mutation was chosen for sub-cloning and for HiSpeed Plasmid Maxi preparation.  
 
Figure 4.4: Agarose gel (0.8%) showing nine pEF.6 
plasmids presumably containing the K575M Smo. 
Plink, pEF.6 Smo wt and the nine isolated pEF.6 
K575M-Smo plasmids (lane 2-10) were run on a 0.8% 
agarose gel. Plink and pEF.6 Smo wt were run as 
controls. The term “plink” stands for pEF.6 
polylinker, a pEF.6 empty vector, and should 
therefore be smaller than pEF.6 K575M-Smo 
plasmids, containing a mutated insert. The 1 kb Plus 
DNA ladder was used as molecular size marker.  
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4.2 SUB-CLONING: Insertion of R484W-, L514F-, S533N-, 
W535L-, K575M-Smo and Smo wt into the p3xFLAG-CMV-
10 vector  
To accomplish the sub-cloning, an EcoRI restriction site was generated in the wt and five 
mutated Smo. The EcoRI restriction site was generated adjacent to the ATG start codon of 
the various Smo constructs, using primer pEF.6 29U31 and pEF.6 202L18. The primer 
pEF.6 29U31 contains a “mismatch” that introduces an EcoRI restriction site in the various 
Smo constructs. The products were analysed on 1% agarose gel, and the observed product 
size was as expected approximately 2500 bp (calculated 2517 bp) (Figure 4.5). These 
products were isolated and purified from the agarose gel. The five Smo mutants, wt and the 
empty vector p3xFLAG-CMV-10 (Figure 4.7) were digested with EcoRI (10 units/µl) and 
XbaI (20 units/μl), and subsequently separated on a 1% agarose gel. The fragment sizes of 
the Smo mutants and p3xFLAG-CMV-10 vector were approximately 2400 and 6300 bp as 
calculated (2422 and 6262 bp), respectively (Figure 4.6). These fragments were isolated and 
purified. The digested Smo wt and mutated versions were ligated into equally cut p3xFLAG-
CMV-10 vector by T4 DNA ligase. A control experiment of the p3xFLAG-CMV-10 vector 
was performed by restriction digestion (Section 4.2.1), verifying that the vector actually was 
an intact vector (Figure 4.8).  
 
Figure 4.5: Agarose gel (1%) showing PCR-products with a generated EcoRI restriction site. The EcoRI 
restriction site was generated using primer pEF.6 29U31 and pEF.6 202L18. The primer pEF.6 29U31 contains 
a “mismatch” that introduces an EcoRI site adjacent to the ATG start codon of the various Smo constructs. The 
fragment sizes of the products are of size approximately 2500bp. The 1 kb Plus DNA ladder (left lane on A-C) 
was used as a molecular size marker. A: pEF.6 R484W-, L514F-, and S533N-Smo products. B: pEF.6 K575M-
Smo. C: pEF.6 Smo wt, pEF.6 S533N-Smo and pEF.6 W535L-Smo.  
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Figure 4.6: Agarose gel (1%) showing Smo mutants in p3xFLAG-CMV-10 vector digested with the 
restriction enzymes EcoRI and XbaI. The sizes of the digested p3xFLAG-CMV-10 vectors (A1-3 and B5-7) 
were 6262bp, and the digested p3xFLAG-CMV-10 Smo mutants (A4-6 and B1-4) were 2422 bp. The 1 kb 
Plus DNA ladder was used as a molecular size marker (left lane on A-B). A: The p3xFLAG-CMV-10 vector 
(lane 1) was digested with EcoRI and XbaI, isolated and purified for subsequent ligation. Lane 2 displays 
p3xFLAG-CMV-10 vector only digested with XbaI, and lane 3 displays the vector only digested with EcoRI. 
Lane 4, p3xFLAG-CMV-10 R484W-Smo; lane 5, p3xFLAG-CMV-10 L514F-Smo; and lane 6, p3xFLAG-
CMV-10 S533N-Smo. Each p3xFLAG-CMV-10 Smo mutant were digested with EcoRI and XbaI. B: 
p3xFLAG-CMV-10 vector (lane 5-7). Lane 5; p3xFLAG-CMV-10 vector digested with EcoRI and XbaI. Lane 
6; vector digested with only EcoRI, and lane 7; digested with XbaI. Lane 1, p3xFLAG-CMV-10 Smo wt; lane 
2,; p3xFLAG-CMV-10 S533N-Smo; lane 3, p3xFLAG-CMV-10 W535L-Smo; and lane 4, p3xFLAG-CMV-
10 K575M-Smo. 
 
 
Figure 4.7: p3xFLAG-CMV-10 vector from Sigma-Aldrich. The five fragments containing mutated 
versions of Smo and Smo wt were ligated into the p3xFLAG-CMV-10 vector in the EcoRI and XbaI restriction 
sites of the vector. 
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4.2.1 Verification of the p3xFLAG-CMV-10 vector  
The p3xFLAG-CMV-10 empty vector was digested with the restriction enzymes SmaI and 
NcoI as a control experiment, showing that the vector was intact. Treatment with NcoI 
should give four fragments with theoretical sizes of 233, 703, 1004 and 4359 bp, 
respectively, and SmaI-treatment should give two fragments with theoretical sizes of 1983 
and 4316 bp, respectively, if the vector were intact. The fragment sizes determined by 
agarose gel electrophoresis corresponded well with the theoretical sizes (Figure 4.8). The 
p3xFLAG-CMV-10 vector in lane 1 was uncut and circular, and could therefore not directly 
be compared with the linear DNA-fragments of the molecular size marker applied in the left 
lane (Figure 4.8). 
 
 
4.2.2 Quality control of p3xFLAG CMV-10 R484W-, L514F-, S533N-, 
W535L-, K575M-Smo and Smo wt 
“TOP10” competent E. coli bacteria were transformed with one of the five p3xFLAG-CMV-
10 Smo mutants or Smo wt. The transformed bacteria were plated on LB-agar plates with 
ampicillin. Five colonies of each mutant were picked and cultured. The plasmid DNA in 
these bacteria-cultures was isolated in small scale, subsequently sent to DNA sequencing 
and were analysed on 1% agarose gels (Figure 4.9). The isolated plasmids of the various 
mutations of p3xFLAG-CMV-10 Smo had larger sizes than the p3xFLAG-CMV-10 empty 
vector control, indicating that the plasmids contained the expected inserts (Figure 4.9). The 
constructs in lane 1-5 (Figure 4.9 A and B) in addition to the control vector (p3x) are 
Figure 4.8: Agarose gel (1%) showing the 
p3xFLAG-CMV-10 empty vector 
verified with restriction digestion. The 1 
kb Plus DNA ladder was used as a 
molecular size marker (left lane). Lane 1, 
p3xFLAG-CMV-10 uncut control. Lane 2, 
p3xFLAG-CMV-10 digested with SmaI. 
Lane 3, p3xFLAG-CMV-10 digested with 
NcoI.  
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circular plasmids, and not linear DNA-fragments, and should therefore not be compared with 
the linearised 1 kb Plus DNA ladder molecular size marker applied in the left lane (Figure 
4.9 A and B). 
Six primers were used for sequencing of the isolated plasmid inserts, A68V-FW, R199W-
Rev, T349I-FW, S533N-Rev, K575M-FW and P755F-Rev (Table 3.1). The DNA sequences 
from the sequencing-lab (not shown) were analysed and one plasmid with the verified 
correct sequence were chosen for HiSpeed Plasmid Maxi preparation. To verify the insert 
length of the isolated plasmid DNA (from maxi-prep), restriction enzyme analysis was 
performed (Section 4.2.3, figure 4.10).  
 
4.2.3 Restriction enzyme analysis of p3xFLAG-CMV-10 R484W-, L514F-, 
S533N-, W535L-, K575M-Smo, Smo wt and pEF.6 K575M-Smo  
After HiSpeed Plasmid Maxi preparation of p3xFLAG-CMV-10 R484W-, L514F-, S533N-, 
W535L-, K575M-Smo and Smo wt plasmids, the plasmids were digested with Tth111I and 
subsequently analysed on 1% agarose gel (Figure 4.10). The expected product sizes from the 
Figure 4.9: Agarose gel (1%) showing the five 
isolated plasmids for each of the p3xFLAG-
CMV-10 Smo mutations. The p3xFLAG-CMV-
10 vector was run as control (p3x). A I;lane 1-4: 
Four isolated plasmids of p3xFLAG-CMV-10 
R484W-Smo. A II: Five small-scale plasmids of 
p3xFLAG-CMV-10 L514F-Smo plasmid. B I: Five 
small-scale plasmids of p3xFLAG-CMV-10 Smo 
wt. B II: Five small-scale plasmids of p3xFLAG-
CMV-10 W535L-Smo. B III: Five small-scale 
plasmids of p3xFLAG-CMV-10 S533N-Smo. B 
IV: Five small-scale plasmids of p3xFLAG-CMV-
10 K575M-Smo.  
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Tth111I restriction enzyme digestion were 2745 and 5939 bp, respectively (Figure 4.10, lane 
2-7). Tth111I restriction enzyme digestion of the p3xFLAG-CMV-10 vector was expected to 
give one fragment with the size of 6296 bp (Figure 4.10, lane 1). The pEF.6 K575M-Smo 
has only one Tth111I restriction site and Tth111I digestion gave the expected product of size 
7174 bp (Figure 4.10, lane 8). These plasmids were used for transfection of NIH/3T3-cells. 
 
4.3 CELL BASED EXPERIMENTS 
NIH/3T3-cells were transfected with expression constructs according to the protocol 
described in the Methods chapter. Stably transfected cell lines were generated by culturing 
transfected cells in the presence of G-418 (Figure 4.11). Six individual clones of each 
transfection were isolated resulting in forty two potentially monoclonal cell lines (Table 
4.1). The cell lines were analysed by reporter gene assay, real time RT-PCR and Western 
blotting. Reporter gene assay and real-time RT-PCR were used to characterise the 
monoclonal cell lines and determine the expression levels of the transfected constructs. The 
number of analysed monoclonal cell lines in real-time RT-PCR is shown in table 4.1. 
Western blotting was used to demonstrate the expression of Smo proteins from the 
transfected plasmids in stably transfected NIH/3T3-cell lines.  
 
Figure 4.10: Agarose gel (1%) showing 
fragments from Tth111I restriction enzyme 
digestion of Smo-containing plasmids.  
 Lane 1: p3xFLAG-CMV-10 empty vector.  
Lane 2: p3xFLAG-CMV-10 Smo wt.  
Lane 3: p3xFLAG-CMV-10 R484W Smo.  
Lane 4: p3xFLAG-CMV-10 L514F Smo.  
Lane 5: p3xFLAG-CMV-10 S533N Smo.  
Lane 6: p3xFLAG-CMV-10 W535L Smo.  
Lane 7: p3xFLAG-CMV-10 K575M Smo.  
Lane 8: pEF.6 K575M Smo.  
The 1 kb Plus DNA ladder was used as molecular 
size marker (left lane). 
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4.3.1 Gli1 activity in monoclonal cell lines (Luciferase assay) 
Reporter gene assay (Luciferase assay) was used to analyse Gli1 activity in the monoclonal 
cell lines. The monoclonal cell lines were transfected with two independent plasmids: 1) Gli 
BS-Luc (Gli Binding Sequence-Luciferase) plasmid encoding firefly-Luciferase under the 
control of a Gli1 dependent promoter (experimental reporter), 2) the pGL4.74 vector 
encoding Renilla-Luciferase that served as an internal control. Activated Hh signalling 
pathway increased Gli1 activity which resulted in increased expression of firefly-Luciferase. 
Expression of Luciferase was easily monitored by EnVision 2104 Multilabel Reader 
(PerkinElmer).  
Three different experimental approaches were used. In the first experiment the monoclonal 
cell lines were cultured in complete growth medium, and basal Gli1 activity in the various 
monoclonal cell lines was analysed (Figure 4.12). The three cell lines containing p3xFLAG-
CMV-10 empty vector showed different levels of Gli1 activity (Figure 4.12 A), where cell 
line p3xFLAG 6 gave the lowest Gli1 activity. The response in p3xFLAG-CMV-10 empty 
vector transfected cells represents Gli1 activation mediated through endogenously expressed 
components of the Shh/Gli signalling pathway in NIH/3T3-cells. The cells transfected with 
R484W- and L514F-Smo showed a trend of lower gene expression levels compared to the 
other transfected cells containing Smo mutants (except for L514F-Smo number 5). The 
different clones of each Smo expression construct showed variable activation of Gli1, e.g. 
Table 4.1: Monoclonal cell lines for RT-PCR analysis.  Figure 4.11: Flow-chart showing how monoclonal 
cell lines were generated. 
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p3xFLAG-CMV-10 S533N-Smo 1-6. In figure 4.12 B the result shown in panel A have been 
normalised to the p3xFLAG-CMV-10 vector cell line number 6 (p3xFLAG 6). It is difficult 
to identify a pattern between the expression constructs from only one experiment (Figure 
4.12 A and B).  
 
 
Figure 4.12: Gli1 activity expressed as Firefly/Renilla-luciferase ratio in 27 monoclonal cell lines. Stably 
transfected NIH/3T3-cells expressing wt or mutated Smo were transiently cotransfected with Gli BS-Luc and 
Renilla-Luciferase reporter constructs. Firefly-luciferase activity in cell lysates was normalised to Renilla 
luciferase activity. A: Results are expressed as the mean ± standard deviation (SD) of quadruplicates from one 
experiment (n=1). B: The results in A were normalised to p3xFLAG-CMV-10 vector cell line number 6 
(p3xFLAG 6), which was given the value 100. 
In a second experiment the cells were cultured in complete growth medium until confluence 
and then maintained for 18 h in reduced serum medium (Figure 4.13, black columns). In a 
third experimental design the cells were cultured in complete growth medium until 
confluence and then treated with 50:50 (V:V) Shh conditioned medium: 0.5% NCS-DMEM 
(Figure 4.13, grey columns) for 18 h. The Gli1 activity was determined for each 
experimental approach. There was no obvious effect of the Shh conditioned medium (Figure 
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4.13). Based on this single experiment, it is not possible to draw conclusions about the 
signalling properties of the various mutated versions of Smo.  
RT-PCR experiments were performed in parallel with the Luciferase-assay. Based on initial 
experiments we decided to run RT-PCR to verify the monoclonal cell lines. The reporter 
gene assay experiment was therefore only performed once. 
 
Figure 4.13: Gli1 activation expressed as Firefly/Renilla-luciferase ratio in 34 monoclonal cell lines in 
presence or absence of Shh.  Stably transfected NIH/3T3-cells expressing wt or mutated Smo were transiently 
cotransfected with Gli BS-Luc and Renilla-Luciferase reporter constructs. Upon confluency the NIH/3T3-cells 
were serum starved (0.5% NCS DMEM) (black columns), or treated with Shh-conditioned medium (produced 
from EcR293 Shh cells) (grey columns). Gli activity in the cell lines were measured using Luciferase assay kit. 
The luciferase activity in cell lysates was normalised to Renilla luciferase activity. Results are expressed as the 
mean ± standard deviation (SD) of quadruplicates from one experiment (n=1). 
4.3.2 Real time RT-PCR 
Real-time RT-PCR was used for relative quantification of the expression levels of human 
Smo (hSmo), mouse Gli1 (mGli1) and mouse Ptch (mPtch) mRNA in each monoclonal cell 
line.  
4.3.2.1 Analysis of pcDNA 3.1 S533N-, W535L-Smo and Smo wt expression and 
signalling. 
RT-PCR was used to address the signalling properties of Smo wild type and two mutated 
versions of Smo (S533N- and W535L-Smo) inserted in the pcDNA 3.1 vector. These 
constructs and pcDNA 3.1 empty vector (control) were transfected into separately NIH/3T3-
cells.  
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Four experiments were performed measuring the mRNA expression level of hSmo, mGli1 
and mPtch in NIH/3T3-cells containing the various constructs. The different gene expression 
levels in the transfected NIH/3T3-cells were compared to each other (Figure 4.14). The 
white columns show gene expression levels in cells maintained in low serum medium (0.5% 
NCS-DMEM), and the black columns show gene expression levels in cells maintained in 
complete growth medium (5% NCS-DMEM). The pcDNA 3.1 W535L-Smo showed a 
higher expression level of hSmo compared to pcDNA 3.1 Smo wt and S533N-Smo, but the 
difference was not significant (Figure 4.14 A). NIH/3T3-cells transfected with empty vector 
showed minimal hSmo expression (Figure 4.14 A). The pcDNA 3.1 W535L-Smo gave a 
higher expression level of mGli1 compared to the other constructs (Figure 4.14 B). The 
expression level of mPtch did not differ between the different constructs (Figure 4.14 C).  
 
Figure 4.14: Messenger RNA expression of hSmo (A), mGli1 (B) and mPtch (C) in NIH/3T3-cells 
quantified by real-time RT-PCR.  Total RNA was isolated from stably transfected NIH/3T3-cells with the 
various constructs in pcDNA 3.1. The white columns show gene expression levels in cells maintained in low 
serum medium (0.5% NCS-DMEM), and the black columns show gene expression levels in cells maintained in 
complete growth medium (5% NCS-DMEM). The mRNA expression levels are presented relative to the 
expression of the reference gene GAPDH in each sample. The data are expressed as mean ± SEM of triplicates 
from four independent experiments (n=4).  
As a positive control for the RT-PCR analysis, NIH/3T3-cells transfected with pcDNA 3.1 
empty vector were treated with Shh-conditioned medium (Figure 4.15). Minimal hSmo 
expression was observed in the NIH/3T3-cells (Figure 4.15 A). Figure 4.15 B and C show 
that mGli1 and mPtch expression levels are increased when the NIH/3T3-cells were treated 
with Shh-conditioned medium. In the cells transfected with empty vector the Hh signalling 
pathway became activated through endogenously expressed pathway members.  
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Figure 4.15: Messenger RNA expression of hSmo (A), mGli1 (B) and mPtch (C) in NIH/3T3-cells 
transfected with pcDNA 3.1 empty vector quantified by real-time RT-PCR.  Total RNA was isolated from 
NIH/3T3-cells stably transfected with the pcDNA3.1 empty vector. The white columns show gene expression 
levels in cells maintained in low serum medium (0.5% NCS-DMEM), and the black columns show gene 
expression levels in cells maintained in complete growth medium (5% NCS-DMEM). The stribed columns 
show gene expression levels in cells treated with 50:50 (V:V) Shh conditioned medium:0.5% NCS-DMEM. 
The mRNA expression levels are presented relative to the expression of the reference gene GAPDH in each 
sample. The data are expressed as mean ± SEM, n=4.  
4.3.2.2 Verification of monoclonal cell lines  
Each confluent monoclonal cell line (Table 4.1) was prepared for analysis as described in the 
Methods chapter (section 3.7.2). As previously mentioned, real-time RT-PCR was used to 
detect and relatively quantify the relative expression levels of hSmo, mGli1, mPtch mRNA 
in each monoclonal cell line. Calculation of the original mRNA in the sample was performed 
as described in section 3.7.2.6, and presented in figure 4.16-4.26. The data were analysed in 
three ways: 
1. The hSmo (Figure 4.16) mGli1 (Figure 4.17) and mPtch (Figure 4.18) mRNA 
expression levels in the monoclonal cell lines are presented in separate graphs. 
Figure 4.16 shows that the three monoclonal cell lines transfected with p3xFLAG-
CMV-10 empty vector expressed minimal hSmo mRNA indicating that the primers 
were specific for human Smo. NIH/3T3-cells transfected with R484W-, L514F- and 
S533N-Smo shows relatively low hSmo mRNA expression levels compared to cells 
transfected with W535L-, K575M-Smo and Smo wt. The data show high variability.  
W535L 4 shows high expression level of mGli1 mRNA compared to the other 
constructs in figure 4.17. The monoclonale cell lines containing the various 
expression constructs showed variable degree of mPtch mRNA expression level in 
figure 4.18.  
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2. Mouse Gli1 mRNA expression level is expressed relative to hSmo mRNA expression 
level within each cell line. This was done with every cell line, but only one graph is 
shown as an example (Figure 4.19). Expression levels of mGli1 mRNA relative to 
hSmo mRNA from six monoclonal cell lines containing p3xFLAG-CMV-10 L514F-
Smo are shown in figure 4.19. The expression levels of mGli1 and hSmo mRNA is 
approximately equal in L514F 1, 4 and 5.  
3. The expression levels of hSmo, mGli1 and mPtch mRNAs were analysed in every 
one of the monoclonal cell lines, and the data from the various cell lines are 
presented in separate graphs (Figures 4.20- 4.26). The data presented in figure 4.20-
4.26 show high variability. Figure 4.20 A-C show that the three cell lines containing 
p3xFLAG-CMV-10 empty vector had minimal expression of hSmo mRNA. The 
p3xFLAG 3 showed the highest mGli1 mRNA expression level. Figure 4.21 A-D 
show expression levels of hSmo, mGli1 and mPtch mRNAs in four monoclonal cell 
lines containing p3xFLAG-CMV-10 Smo wt. Smo wt 1 showed the highest hSmo 
mRNA expression level compared to the other cell lines, but had very low mGli1 
expression level. Smo wt 2 had approximately equal hSmo mRNA and mGli1 mRNA 
expression levels. Figure 4.22 A-D show expression levels of the three genes in four 
monoclonal cell lines containing p3xFLAG-CMV-10 R484W-Smo. R484W 2 
showed highest hSmo mRNA expression level compared to the other cell lines, but 
mGli1 mRNA expression level was low. Figure 4.23 show expression levels of the 
three genes in six monoclonal cell lines containing p3xFLAG-CMV-10 L514F-Smo. 
L514F 2 had the highest expression level of hSmo mRNA and mGli1 mRNA 
compared to the other cell lines. Figure 4.24 shows expression levels of hSmo, mGli1 
and mPtch mRNAs in six monoclonal cell lines containing p3xFLAG-CMV-10 
S533N-Smo. S533N 4 contained highest hSmo mRNA expression level andthe 
mGli1 expression level was relatively low. Figure 4.25 shows expression levels of 
hSmo, mGli1 and mPtch mRNAs in four monoclonal cell lines containing p3xFLAG-
CMV-10 W535L-Smo. W535L 3 and 4 contained highest level of hSmo mRNA 
compared to the other cell lines. W535L 4 contained higher mGli1 expression level 
compared to W535L 3. Figure 4.26 shows expression levels of hSmo, mGli1 and 
mPtch mRNAs in six monoclonal cell lines containing p3xFLAG-CMV-10 K575M-
Smo. K575M 4 contained very high hSmo mRNA expression level compared to the 
other cell lines, but mGli1 mRNA expression level was low. 
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Figure 4.16: Messenger RNA expression of hSmo in various monoclonal cell lines. The values 
obtained are normalized to the reference gene GAPDH. Data are expressed as the mean ± standard 
deviation (SD) of triplicates from three experiments (n=3).
Figure 4.17: Messenger RNA expression of mGli1 in various monoclonal cell lines. The values 
obtained are normalized to the reference gene GAPDH. Data are expressed as the mean ± standard 
deviation (SD) of triplicates from three experiments (n=4).
Figure 4.18: Messenger RNA expression of mPtch in various monoclonal cell lines. The values 
obtained are normalized to the reference gene GAPDH. Data are expressed as the mean ± standard 
deviation (SD) of triplicates from three experiments (n=4).
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2.  
 
 
3.
 
 
 
 
 
 
Figure 4.20: Expression levels of hSmo, mGli1 and mPtch mRNAs in three monoclonal cell lines 
containing p3xFLAG-CMV-10 empty vector. The values obtained are normalized to the reference gene 
GAPDH. Data are expressed as the mean ± standard deviation (SD) of triplicates from three experiments 
(n=3) for hSmo, and four experiment for mGli1 and mPtch (n=4). Cell lines: p3xFLAG 2 (A), p3xFLAG 3 
(B) and p3xFLAG 6 (C). 
Figure 4.21: Expression levels of hSmo, mGli1 and mPtch mRNAs in four monoclonal cell lines 
containing p3xFLAG-CMV-10 Smo wt. The values obtained are normalized to the reference gene 
GAPDH. Data are expressed as the mean ± standard deviation (SD) of triplicates from three experiments 
(n=3) for hSmo, and four experiment for mGli1 and mPtch (n=4). Cell lines: Smo wt 1(A), Smo wt 2 (B), 
Smo wt 3 (C) and Smo wt 6 (D).  
Figure 4.19: Expression level of mGli1 mRNA 
relative to hSmo mRNA in six monoclonal cell 
lines containing p3xFLAG-CMV-10 L514F-Smo.
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Figure 4.22: Expression levels of hSmo, mGli1 and mPtch mRNAs in four monoclonal cell lines 
containing p3xFLAG-CMV-10 R484W Smo. The values obtained are normalized to the reference gene 
GAPDH. Data are expressed as the mean ± standard deviation (SD) of triplicates from three experiments 
(n=3) for hSmo, and four experiment for mGli1 and mPtch (n=4).  Cell lines: R484W 1 (A), R484W 2 (B), 
R484W 4 (C) and R484W 5 (D).  
Figure 4.23: Expression levels of hSmo, mGli1 and mPtch mRNAs in six monoclonal cell 
lines containing p3xFLAG-CMV-10 L514F Smo. The values obtained are normalized to the 
reference gene GAPDH. Data are expressed as the mean ± standard deviation (SD) of 
triplicates from three experiments (n=3) for hSmo, and four experiment for mGli1 and mPtch 
(n=4). A-F: Gene expression levels in cell line number L514F 1-6, respectively. 
64 
 
 
 
 
 
 
Figure 4.24: Expression levels of hSmo, mGli1 and mPtch mRNAs in six monoclonal cell 
lines containing p3xFLAG-CMV-10 S533N Smo. The values obtained are normalized to the 
reference gene GAPDH. Data are expressed as the mean ± standard deviation (SD) of triplicates 
from three experiments (n=3) for hSmo, and four experiment for mGli1 and mPtch (n=4). A-F: 
Gene expression levels in cell line number S533N 1-6, respectively. 
Figure 4.25: Expression levels of hSmo, mGli1 and mPtch mRNAs in four monoclonal 
cell lines containing p3xFLAG-CMV-10 W535L Smo. The values obtained are normalized 
to the reference gene GAPDH. Data are expressed as the mean ± standard deviation (SD) of 
triplicates from three experiments (n=3) for hSmo, and four experiment for mGli1 and mPtch 
(n=4). A-D: gene expression levels in cell line number W535L 1-4, respectively. 
65 
 
 
 
Figure 4.26: Expression levels of hSmo, mGli1 and mPtch mRNAs in six monoclonal cell 
lines containing p3xFLAG-CMV-10 L514F Smo. The values obtained are normalized to the 
reference gene GAPDH. Data are expressed as the mean ± standard deviation (SD) of triplicates 
from three experiments (n=3) for hSmo, and four experiment for mGli1 and mPtch (n=4). A-F: 
Gene expression levels in cell line number K575M 1-6, respectively. 
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4.3.3 Western blotting 
Samples from stably transfected polyclonal cell lines were prepared for Western blot as 
described in the Methods chapter (section 3.7.3 – 3.7.5). Figure 4.27 shows proteins at 
approximate sizes of 75 and 100 kDa detected by Western blotting in lysates of NIH/3T3-
cells transfected with various constructs. The expected protein size of the Smo was 86.4 
kDa. The anti-FLAG M2 antibody was supposed to bind Flag-tagged Smo expressed in 
NIH/3T3-cells transfected with various Smo expression constructs. The same bands were 
also seen in the samples transfected with empty vector, indicating that the anti-FLAG M2 
antibody binds non-specifically. 
  
 
 
 
 
 
Figure 4.27: Western blot showing proteins from NIH/3T3-cells transfected with various constructs. The 
protein samples were run on 6% acrylamide gel and subsequently transferred to a nitrocellulose membrane when 
using Odyssey Infrared Imaging System. Primary antibody used was monoclonal anti-FLAG M2 from Sigma  
(dilution 1:1000). Secondary antibody used was donkey anti-mouse IR Dye from Odyssey. The Precision Plus 
Protein Dual Color Standards (Bio-Rad) was used as a protein marker.  
Lane 1: p3xFLAG-CMV-10 empty vector. Lane 2: p3xFLAG-CMV-10 Smo wt. Lane 3: p3xFLAG-CMV-10 
R484W-Smo. Lane 4: p3xFLAG-CMV-10 L514F-Smo. Lane 5: p3xFLAG-CMV-10 S533N-Smo. Lane 6: 
p3xFLAG-CMV-10 W535L-Smo. Lane 7: p3xFLAG-CMV-10 K575M-Smo. 
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5. DISCUSSION 
5.1 METHODOLOGICAL CONSIDERATIONS 
When evaluating the results presented in this thesis, it is important to bear in mind that the 
methods used to obtain these results have certain limitations. 
5.1.1 Traditional PCR and agarose gel electrophoresis 
In this study traditional RT-PCR was used to generate the K575M-encoding sequence from 
the Smo wt sequence and to generate an EcoRI restriction site in the six following 
constructs: pEF.6 R484W-, L514F-, S533N-, W535L- , K575M-Smo and Smo wt. Agarose 
gel electrophoresis was used to identify and isolate the PCR-products, and to separate and 
purify restriction fragments for ligation reactions, and for quality control of the various 
plasmid constructs.  
Traditional PCR involves several reaction components that may influence the final amplicon 
products like template, primers, reaction buffer, dNTP mix and thermostable DNA 
polymerase. Sometimes we obtained little or no PCR-products (not shown in this thesis) 
after running them on agarose gels. Non-visible bands can be caused by poor PCR primer 
design, DNA template containing inhibitors (reagents such as DMSO, SDS and formamide), 
too low template concentration, too high annealing temperature or too low primer 
concentration. When performing traditional PCR you should be aware of these factors. In 
some agarose gel analysis unexpected bands were observed (Figure 4.5 B), which may be 
caused by primer-dimer formation, non-specific annealing of primers to template or 
contaminated DNA from exogenous sources [78].  
5.1.2 Analysis of cell experiments 
The cell-based experiments were performed on transfected NIH/3T3-cells. The methods 
used to obtain results from these cells have certain limitations and the final results may be 
influenced by many factors. One of the most important factors is the transfection efficiency, 
which may be affected by many parameters including the cell culture conditions and the 
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quality of the used vector. Too low or too high cell densities at the time of transfection may 
result in poor uptake of the transfection complexes and insufficient expression of the 
transfected genes. Poor plasmid DNA quality may also affect the transfection efficiency 
negatively, and may be a result of poor plasmid purification or endotoxin contamination 
during the purification process. Endotoxins are cell membrane components of Gram-
negative bacteria (e.g. E. coli) that are released during the lysis step of plasmid preparation. 
Transfection efficency are, however, never 100%, and as a consequence, some cells remain 
without the desired plasmid, and thus do not express the protein it encodes.  
Primarily, the real-time RT-PCR method is considered in this section, because it is the main 
method used among the cell-based experiments in this project. 
5.1.2.1 Gene-reporter assay 
Running luciferase-assay includes rough treatment of the cells. At first, the cells were 
transfected with different expression vectors, and subsequently stabilised with G-418 
antibiotics. By establishing stable cell lines, experimental variation due to differences in 
transfection efficiencies may be avoided [79]. These stably transfected cells were co-
transfected (transient transfection) with reporter gene constructs; one internal and one 
experimental construct. As mentioned above there are many parameters affecting 
transfection efficiencies and transfecting the cells twice increases the risk of achieving 
variable results.   
  
5.1.2.2 Real-time RT-PCR 
In this study real-time RT-PCR was used to determine the mRNA levels of different genes in 
the Hh signalling pathway. All values were normalised to glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH), and some experiments were also evaluated to the normalisation 
gene TATA box binding-protein (Tb-p). Real-time RT-PCR is a sensitive method of 
comparing the expression of selected genes between different samples. The specificity and 
sensitivity make it possible to detect small differences in mRNA expression. The method has 
a large dynamic range and potential for high throughput as well as accurate quantification 
[80]. Real-time RT-PCR is based on the assumption that there is a quantitative relationship 
between the amount of template present at the beginning of the reaction and amount of PCR-
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product at any given cycle. The quantitation relies on the Ct values determined during the 
detectable exponential phase of the PCR, and on the standard curve [81]. The standard curve 
was used to calculate original mRNA amount based on estimated amplification efficiency. 
Real-time RT-PCR analysis of cellular mRNA expression involves many technical steps that 
may influence the final outcome, including the preparation of cells, isolation of RNA, first 
strand cDNA synthesis and finally the polymerase chain reaction [80]. The quality and 
density of cells in the sample, the isolation of pure RNA and accuracy in the cDNA 
synthesis and the use of primers and type of housekeeping gene during PCR are important 
for the reliability of the final result. A small amount of contamination during these processes 
may affect the analysis significantly. 
Isolation of RNA: RNA, isolated from the cells, is extremely delicate once removed from its 
cellular environment. RNA isolation and purification is more complicated than of DNA 
which is more stable, and a template suitable for inclusion in an RT-PCR assay must be of 
highest quality if quantitative results are wanted [76]. After performing RNA isolation, the 
RNA should be undegraded and free of protein and DNA (DNAse treated). The evaluation 
of RNA integrity by inspection of the 28 S and 18 S rRNA bands was accomplished by the 
use of agarose gel electrophoresis. The sample purity as well as concentration was also 
assessed spectrophotometrically.   
Normalisation: To control for error in real-time RT-PCR, it is important to make use of a 
correct normalisation strategy. Normalisation remains one of real-time RT-PCRs most 
difficult problems. Several strategies have been proposed for normalising real-time RT-PCR 
data [80]. One accepted method for minimising the mentioned errors and correcting for 
sample-to-sample variation is to amplify, simultaneously with the RNA-samples, a cellular 
RNA that serves as an internal reference against which other RNA values may be 
normalised. The ideal internal standard should be expressed at a constant level among 
different tissues of an organism, at all stages of development, and should be unaffected by 
the experimental treatment. Additionaly, an internal control should also be expressed at 
roughly the same level as the RNA under study [81].  
The mRNA encoding GAPDH is frequently used as an endogenous control for quantitative 
RT-PCR analysis. However, there is evidence suggesting that its use as an internal standard 
is inappropriate [82, 83]. The GAPDH expression level seems to vary between different 
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individuals and during the cell cycle [81]. As mentioned the values obtained in the current 
project were all normalised to GAPDH, whereas some experiments were also normalised to 
the normalisation gene Tb-p. Human Smo expression level in one RT-PCR experiment was 
analysed relative to both GAPDH and Tb-p and both normalisation genes gave 
approximately the same pattern of hSmo expression level in the various monoclonal cell 
lines. Therefore, all data from RT-PCR showed in the Results section are only normalized to 
GAPDH.  
Specific primers: SYBR Green and Taqman probe were used to detect and quantify PCR-
products in real-time PCR reactions. The disadvantage of using SYBR Green to detect and 
quantify PCR-products is that it may bind to any double-stranded DNA in the reaction, 
including primer-dimers and other non-specific reaction products, which results in an 
overestimation of the target concentration. To avoid such disadvantages this method requires 
specific primers. To confirm that the measured gene expression levels were not affected by 
primer dimerisation, primers were tested by melting point analysis. Probe based (Taqman) 
PCR is a more reliable quantification method since a single fluorophore is only released 
from quenching when a specific amplified molecule is synthesized, avoiding detection of 
unspecific products.  
5.1.2.3 Western blotting 
Primarily, Western blotting was used to detect Smo-protein expression in polyclonal 
NIH/3T3-cells. Western blotting involves many technical steps that may affect the final 
outcome. Sources of error that can contribute to the reliability of the results are the quality of 
the cells, protein sample processing of the cells, protein quantification, loading of proteins 
on the gel, transfer of proteins to membrane and attachment and quality (specificity) of 
primary and secondary antibodies to the membranes. The bands on the membranes are 
evaluated visually in relation to the other bands on the same membrane and the protein 
standard. In essence this involves detecting the sizes of the proteins and the intensity of the 
bands. The appearance of the bands, their intensity and background noise may influence 
calculations of band density. These factors make it difficult to determine accurately the 
relative band densities and accounts for large variability in density measurements.  
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5.2 INTERPRETATION OF THE RESULTS 
5.2.1 Generation of K575M-Smo encoding plasmid 
The K575M-Smo encoding plasmid was successfully generated in the laboratory. The 
K575M-encoding sequence was generated from the Smo wt sequence in a PCR-based 
mutagenesis approach. It is well known that the polymerase enzymes used for PCR may 
make mistakes and insert another nucleotide than the one present in the template. In this 
thesis, the high fidelity Vent DNA polymerase was used for all PCR reactions to reduce the 
problem with PCR-introduced unwanted mutations. The fidelity of Vent is 5-15 times higher 
than what has been observed for Taq DNA polymerase and potential problems with PCR-
induced mutations should be minimal [84, 85]. The generated K575M-Smo encoding 
construct was sequenced to verify that no unwanted mutations had been introduced during 
the PCR reactions. Alignment of the sequenced construct and the "original" Smo wt 
sequence showed that the PCR reactions had been completed without introducing unwanted 
mismatches.  
Using high fidelity polymerases for this kind of PCR-based mutagenesis protocols may 
cause some additional challenges. The high fidelity polymerase may also "correct" the 
mismatches introduced by the primers in the first set of PCR reactions. Therefore, several 
potential K575M-Smo constructs were sequenced. Five of the nine sequenced constructs 
showed the intended K575M-Smo mutation and no additional PCR-introduced mutations. 
This PCR-based mutagenesis protocol using the Vent DNA polymerase proved to be reliable 
and efficient to generate point mutations. One of the K575M-Smo plasmids with the verified 
correct sequence was used for sub-cloning and subsequent cell based experiments to address 
the signalling properties of this mutated version of Smo.    
5.2.2 Signalling properties of R484W-, L514F-, S533N-, W535L-, and 
K575M-Smo 
Real-time RT-PCR was used for relative quantification of hSmo, mGli1 and mPtch mRNA 
expression levels in the established monoclonal cell lines. Primer specific for human Smo 
was used to determine if the cells contained the transfected Smo. It was desirable to identify 
cell lines expressing the transfected human Smo at relatively equal levels. Mouse Gli1 and 
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Ptch expression levels were measured to determine the signalling properties of the mutated 
versions of Smo. Increased expression levels of mGli1 and mPtch in cell lines transfected 
with a Smo-mutant compared to cell lines transfected with Smo wt might indicate 
constitutive activity of the mutated version of Smo. 
5.2.2.1 Analysis of the pcDNA3.1 S533N-, W535L-Smo and Smo wt expression and 
signalling 
The objective of these experiments was to address the signalling properties of S533N- and 
W535L-Smo by comparing expression levels of mGli1 and mPtch mRNA in S533N-, 
W535L-Smo and Smo wt cell lines. NIH/3T3-cells transfected with empty vector showed 
minimal hSmo mRNA expression as expected since the primers are specific for human Smo. 
The minimal signal might be caused from unspecific priming. The S533N-Smo showed no 
increase in mGli1 or mPtch mRNA levels compared with Smo wt. However, the W535L-
Smo construct showed increased mGli1 mRNA expression, but no changes in mPtch mRNA. 
On the other hand, Shh conditioned medium increased both mGli1 and mPtch mRNA 
indicating that the point of pathway activation may influence gene regulation. The genes 
targeted by Shh include Gli1, Ptch and Hip, thus Shh stimulation should result in increased 
levels of Gli1 and Ptch. If the W535L-Smo is constitutive active in this system (transfected 
into NIH/3T3-cells), increased mPtch mRNA could be expected. Possible explanations for 
the observed failure of the W535L-Smo to increase the level of mPtch mRNA might be: 
o When the Hh signalling pathway is activated downstream of Ptch, not all the 
pathway components usually activated by ligand become activated and consequently 
no mPtch mRNA increase is observed for the W535L-Smo induced activation of the 
pathway.  
o Ptch-silencing through DNA promoter methylation. DNA methylation occurs by 
covalent addition of a methyl group to the DNA, and these methyl groups project 
into the major groove of DNA and effectively inhibit transcription [86]. Ptch-
silencing through DNA promoter methylation has been shown in medulloblastoma 
and acute myeloid leukemia [87-90]. Proper demethylation of the promoter may 
require ligand induced activation of the Hh signalling pathway. 
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However, another explanation might be that the W535L-Smo shows no constitutive activity 
in the system used in this thesis work. W535L-Smo are expected to show constitutive 
activity based on  reports from Low W.C. et al [70] and Xie J. et al [68]. Low W.C. et al. 
[70] showed that W535L-Smo was constitutive active analysing Shh-light cells with gene 
reporter assay. The Shh-light cells contained a stably integrated Gli-dependent firefly 
luciferase reporter and a Renilla luciferase reporter control and were infected with a 
retrovirus containing Smo wt and W535L-Smo cDNAs. Xie J. et al. investigated the 
oncogenic potential of the W535L-Smo missense mutation in BCCs, transfecting rat 
embryonic fibroblast REF52 cells with E1A together with wild-type or W535L-Smo and 
assessed for focal cells overgrowth. Focal cells overgrowth indicate oncogenic potential, and 
this was identified in REF52 cells with E1A and W535L-Smo [68]. Previously reports have 
not identified oncogenic properties for W535L-Smo in the system we have used in this thesis 
work. 
Based on these results we decided to make tagged Smo expression constructs into a new 
vector, the p3xFLAG-CMV-10 vector, aiming at increasing the detection possibilities using 
this vector. The vector encodes three adjacent FLAG-epitopes that will be expressed as a 
fusion protein with Smo. Use of this expression vector provides several advantages: 
o Separation of transfected and tagged Smo from endogenous Smo.  
o Antibiotic selection, as the vector contains the G-418 (geneticin) resistance gene. 
o Detection of expression levels using an antibody specific against p3xFLAG-tag 
(Western blotting), and by specific primers in quantitative PCR. 
5.2.2.2 Verification of monoclonal cell lines: Analysis of the p3xFLAG-CMV-10 
R484W-, L514F-, S533N-, W535L-, K575M-Smo and Smo wt expression and signalling. 
The five mutated versions of Smo and Smo wt as well as p3xFLAG-CMV-10 empty vector 
transfected cell lines were analysed by a gene reporter, RT-PCR and Western blotting 
assays. In the cells transfected with empty vector the Hh signalling pathway may become 
activated through endogenously expressed pathway members. 
Due to time limitations it was decided to determine the Smo mRNA expression in the 
monoclonal cell lines performing real-time RT-PCR based on the initial experiments with 
the pcDNA3.1 Smo cell lines. Furthermore, real-time RT-PCR was preferred versus the gene 
reporter assays due to the need for an additional set of transfections in this assay and the 
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uncertainty of transfection efficiency. High cotransfection efficiency is difficult to obtain, 
due to the many parameters that may affect the transfection including the cell densities, 
DNA concentrations, transfection reagent and incubation time. Based on the single gene 
reporter assay performed, it is not possible to conclude about the signalling properties of the 
various mutated versions of Smo. However, the cells transfected with R484W- and L514F-
Smo showed a trend towards lower gene reporter activity compared to the other mutants of 
Smo (except for L514F 5), indicating that the R484W- and L514F-Smo mutations may result 
in impaired rather than increased pathway activation. Considering the gene reporter assay 
addressing Gli activation in 34 monoclonal cell lines treated with or without Shh conditioned 
medium, there were no stimulatory effect of this medium, as the Gli1 activity from the 
various cell lines was approximately equal (Figure 4.13). The Shh level in the conditioned 
medium may be low due to plating of too few EcR293 Shh cells. This experiment was 
performed only once, and it is therefore not possible to conclude about the signalling 
properties of the various mutated versions of Smo from this experiment.   
Using real-time RT-PCR, the mRNA expression levels of hSmo, mGli1 and mPtch were 
analysed in the Smo monoclonal cell lines, aiming at identifying cell lines expressing the 
transfected human Smo. Constitutively active Smo should increase the Hh signalling 
pathway activity and result in increased mGli1 and mPtch mRNA expression levels. When 
analysing the relationship between mGli1 and hSmo mRNA expression within the various 
cell lines, the expression levels of each gene should also be analysed as explained below 
(See the hypothesis figure 5.1 described below). 
Hypothesis: Two hypothetic cell lines express constitutively active receptors (marked *) but 
with different expression levels (Figure 5.1). Cell line 1 contains lower gene expression level 
of hSmo* and mGli1 mRNA compared to cell line 2 (Figure 5.1 A). When analysing the 
mGli1/hSmo* ratio in cell line 1 and 2 (Figure 5.1 B), it seems that they are of same value, 
but as shown in A the cell lines have different expression levels. Selecting a cell line for 
further studies, cell line number 2 are preferred, because this cell line contains higher 
expression levels of hSmo* and mGli1 mRNA compared to cell line 1.  
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Figure 5.1: Two hypothetic cell lines (1 and 2) containing constitutively active Smo-receptors (hSmo*) 
with different expression levels of hSmo and mGli1. A, gene expression levels of hSmo* and mGli1 in cell 
line 1 and 2. B, mGli1/hSmo* expression ratio in cell line 1 and 2.  
The data from the real-time RT-PCR was analysed according to this hypothesis. For 
example, when analysing data from the cell lines containing p3xFLAG-CMV-10 L514F-
Smo, the mGli1/hSmo-data showed that L514F 1-6 expressed more hSmo than mGli1 
mRNA, but L514F 1, 4 and 5 were approximately equal, indicating that there were greater 
mGli1 mRNA expression levels in these cell lines. Considering the expression levels of each 
gene in the monoclonal cell lines, L514F 5 had higher expression level of hSmo and mGli1 
mRNA compared to L514F 1 and 4. L514F 5 may therefore be a candidate for further 
studies, but the expression data from this and the other cell lines showed high variability and 
the results were difficult to interpret and more studies need to be performed before any 
conclusion can be drawn. Verification of the various Smo-mutant monoclonal cell lines 
turned out to be complicated. After analysing the data from the real-time RT-PCR 
experiments, it is difficult to conclude about the signalling properties of the various mutated 
versions of Smo. The data from the real-time RT-PCR analyses also showed high variability. 
A possible explanation is the many technical steps that might influence the final outcome 
when performing real-time RT-PCR, as discussed above (section 5.1.2.2). To reduce the 
variability in the real-time RT-PCR experiments equal numbers of cells were plated to 
achieve cell confluence at the same time. However, not every cell line obtained confluence 
simultaneously and RNA had to be isolated from cell dishes with varying degree of cell 
density. Isolation of RNA from cells with unequal density might influence the signalling 
properties of the Hh-pathway and the amount of mRNA for the Hh-signalling pathway 
members [91]. This might contribute to the great variability of the obtained data. As 
mentioned in the Background chapter, Smo is enriched in primary cilia when Ptch-mediated 
inhibition of Smo is repealed, and cilia formation is formed when cells reach confluence. 
Smo enrichment in primary cilia is thought to drive activation of target genes like mGli1 and 
76 
mPtch [91]. Other contributions to the high variability of the data between the experiments 
might be unequal RNA quality or cDNA-synthesis. To control for possible genomic DNA 
contamination, cDNA-synthesis reactions were carried out without reverse transcriptase as a 
negative control. These samples were always negative in the RT-PCR reactions, indicating 
that the RNA-samples did not contain genomic DNA. Unstable cell lines might also be an 
explanation to the great data variability, because when the cells have been in culture for long 
time the number of transfected cells might decrease in unstable cell lines. Another 
explanation for the great variability could be that the p3xFLAG-CMV-10 vector may not be 
a suitable vector for the performed experiments. The pcDNA 3.1 vector seems to maintain 
the expected signalling properties better than the p3xFLAG-CMV-10 vector, due to the 
pcDNA3.1 vector gave a trend of constitutive activity of the W535L-Smo as expected from 
previously reports [66-69]. In addition, design of specific primers targeting the FLAG-tag 
and hSmo in the p3xFLAG-CMV-10 vector turned out to be difficult. All primers were 
analysed by the computer programme BLAST to verify their specificity (data not shown), 
but melting point analysis of the real-time RT-PCR products showed non-specific products, 
indicating that the primers gave more than one product. Therefore real-time RT-PCR was 
performed with primers specific to the human Smo inserted into the p3xFLAG-CMV-10 
vector. These primers did not prime to endogenously expressed mouse Smo. There was no 
clear trend of constitutive activity for the W535L-Smo, when the Smo construct was 
expressed from the p3xFLAG-CMV-10 vector.  
Several Western blot analyses were performed trying to detect Smo-protein in transfected 
NIH/3T3-cell lines. First, Smo-protein expressed from the pcDNA 3.1 vector was studied. 
This was not successful, due to poor primary antibodies against Smo. With the new 
p3xFLAG-CMV-10 vector the problem with poor primary antibodies was expected to 
diminish, because this vector encodes Smo as a fusion protein with three adjacent FLAG-
epitopes linked to the N-terminus of Smo. On the Western blot the anti-FLAG M2 antibody 
gave two unspecific protein bands not corresponding to the predicted size of Smo. The 
protein bands are unspecific, because the samples transfected with empty vector showed the 
same bands as for the samples with Smo, indicating that the anti-FLAG M2 antibody binds 
non-specifically.  
 
77 
6. SUMMARY AND PERSPECTIVES 
In summary, the K575M-Smo mutation was successfully generated using a mutagenesis 
reaction containing two sets of PCR reactions. A trend towards constitutive activity of 
W535L-Smo was obtained when analysing the signalling properties of the mutated 
constructs inserted in the pcDNA 3.1 vector, although a significant difference was not 
obtained. Five mutated versions of Smo (R484W-, L514F-, S533N-, W535L- and K575M-
Smo) were analysed, expressed from the p3xFLAG-CMV-10 vector. Analysing the 
signalling properties of the mutated versions of the Smo-receptor turned out to be 
complicated as the results showed great variability. The reason for the complications might 
be:  
o RNA isolation from monoclonal cell lines with various densities influence the 
signalling properties of the Hh-pathway. 
o Unequal mRNA and cDNA quality. 
o Unstable cell lines. 
o Inappropriate expression vector. The pcDNA 3.1 vector seems to maintain the 
expected signalling properties better than the p3xFLAG-CMV-10 vector.  
Based on the variable data from real-time RT-PCR experiments, it is not possible to 
conclude about the signalling properties of the various mutated versions of Smo, and further 
studies must be performed. Re-considering the project, perhaps the experiments should have 
been performed with the expression constructs inserted in the pcDNA 3.1 vector. More 
experiments should be performed with the monoclonal cell lines at equal cell confluence, 
aiming to find cell lines expressing comparable levels of transfected Smo. Other analyses 
should be performed on these cell lines, aiming at determining the signalling properties of 
the mutated versions of the Smo-receptor. 
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8. APPENDIX 
8.1 MATERIALS AND RECIPES 
8.1.1 Chemicals and reagents 
Chemical/Reagent Abbreviation Manufacturer Cat.no 
Absolute (100%) ethanol  Arcus - 
Acrylamide 4K, ultrapure Acrylamide AppliChem - 
Ammonium persulfate APS Bio-Rad - 
Anti-Smoothened Drosophila 
Homolog antibody produced 
in rabbit 
 Sigma S9819 
Bacto-Agar Agar AppliChem A0949.1000 
Bacto-Tryptone Tryptone Merck 1.07213.1000 
Bacto-Yeast extract Yeast extract Merck 1.03753.0500 
BCA Protein Assay Reagent BCA-kit Uptima UP40840A 
Bovine serum albumin 
standard 2mg/ml 
BSA Uptima P36859A 
Cryoprotective medium with 
15% DMSO 
 Lonza 12-132A 
Dimethyl sulfoxide DMSO Sigma D2650 
DNA Ladder, 1Kb Plus  Invitrogen 10787-026 
dNTP Set, 100 mM (100 mM 
each of dATP, dGTP, dCTP 
and dTTP at neutral pH. 
 Invitrogen 10297-018 
Donkey anti-mouse Ig-IR 
Dye 800CW 
 LI-COR Biosciences 926-32212 
Donkey anti-rabbit Ig-HRP  GE Healtcare NA934 
DOW corning®high-vacuum 
silicone grease  
Silicone Sigma-Aldrich Z273554 
Dual-Luciferase® Reporter  Promega E1980 
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1000 Assay System* 
Dulbecco`s Modified Eagles 
Medium, 4.5 g glucose/L 
DMEM Gibco BRL 31966-021 
EcoRI-enzyme  Invitrogen 15202-013 
Ethidium bromide EtBr Sigma E8751 
Fetal bovine serum FBS BioWhittaker DE 14-801F 
Formamide  Sigma F7508 
G-418 sulphate (Geniticin) G418 Gibco BRL 11811-064 
Gli-BS-Luc construct  Sasaki H. et al. - 
Glycerol  Gibco BRL 15514-011 
HiSpeed® Plasmid Maxi Kit 
(25)* 
Maxiprep kit Qiagen 12663 
Isopropanol  Arcus 1-9516 
Lipofectamine 2000 
Transfection Reagent 
Lf-2000 Invitrogen 18324-012 
Lumiglo elite 
(chemiluminescent substrate 
kit)* 
Lumiglo KPL 54-71-00 
Methanol MeOH PROLABO UN1789 
Monoclonal ANTI-FLAG 
M2 antibody produced in 
mouse 
Anti-flag Sigma F1804 
N`N`N`N-tetra-metyl-
ethylene-diamide 
TEMED AppliChem A1148,0100 
NaCl 0,9% B. Braun  Ecotainer 0082489E 
n-butanol  Merck 1.01990.1000 
Newborn calf serum NCS BioWhittaker 
(Cambrex) 
14-416F 
Non-fat dry milk Dry milk Normilk - 
Nuclease-free water (not 
DEPC treated) 
nf-H2O Ambion 9932 
NuSieve 3:1 Agarose Agarose Cambrex 50090 
Oligo (dT)12-18  Oligo dT Invitrogen - 
One Shot TOP 10 Chemically  Invitrogen C4040-03 
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Competent E.coli* 
Optimem Optimem Gibco  51985-026 
p3XFLAG-CMV-10 
expression vector 
p3XFLAG Sigma E4401 
Phosphate buffer salin, 10x 
powder, ultrapure grade 
PBS Amresco - 
Platinum® SYBR® Green 
qPCR SuperMix-UDG w/ 
ROX * 
SYBR-green Invitrogen 11744-500 
Platinum® Quantitative PCR 
SuperMix-UDG w/ROX* 
Platinum SM Invitrogen 11743-500 
Ponasterone A Pon A Invitrogen H101-01 
Precision Plus Protein Dual 
Color Standards 
Protein 
standard 
Bio-Rad 161-0374 
Primers  Invitrogen - 
Probe: GAPDH GAPDH Eurogentec - 
QIAquick Gel Extraction kit 
(250)* 
 Qiagen 28706 
Renilla luciferase pGL4.74-
vector 
Renilla-
luciferase 
Promega  
RNase-Free Dnase Set (50)*  Qiagen 79254 
RNaseOUT Recombinant 
Ribonuclease Inhibitor 
 Invitrogen 10777-019 
RNeasy® Mini Kit (250)*  Qiagen 74106 
SeaKem LE Agarose Agarose Lonza 50004 
Smoothened Antibody  Abcam 60016 
Sodium hydroxide NaOH Merck 1.06469.1000 
Sodium dodecyl sulphate, 
ultrapure, min 99.5% 
SDS Gibco - 
Sodium-ortho-vanadate Na3VO4 Sigma - 
SphI-enzyme SphI New England 
BioLabs 
R0182S 
SuperScript® VILO cDNA 
Synthesis kit* 
 Invitrogen 11754-050 
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SuperScript® III Reverse 
Transcriptase* 
SSIII Invitrogen 18080-044 
T4 DNA Ligase  Invitrogen 15224-017 
TAE buffer**  - - 
Trypsin EDTA/Versene 
(EDTA)  
Trypsin BioWhittaker BE17-161E 
Tryptan Blue Stain 0.4% Tryptan blue Invitrogen T10282 
Tth111I-enzyme Tth111I New England 
BioLabs 
R0185S 
Tween-20 Tween AppliChem A1389,0500 
VentR® DNA Polymerase* Vent New England 
BioLabs 
M0254L 
Wizard® Plus SV Minipreps 
DNA Purification System* 
Miniprep kit Promega A1460 
Zeocin  Invitrogen R250-05  
β-mercapthoethanol, min 
98% 
β-
mercapthoetha
nol 
Sigma M7154 
XbaI-enzyme  Invitrogen R0145S 
*Content of kits are specified in 8.1.2 ** Content of reagents specified in 8.1.3 
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8.1.2  Content of commercial kits 
Kit/Reagent Content/Reagent 
Dual-Luciferase® Reporter 1000 Assay System o Luciferase Assay Buffer II 
o Luciferase Assay Substrate 
(Lyophilized Product) 
o Stop & Glo Buffer 
o Stop & Glo substrate, 50X 
o Passive Lysis Buffer, 5X 
HiSpeed® Plasmid Maxi Kit (25)* o Buffer P1 
o Buffer P2 
o Buffer P3 
o Buffer QBT 
o Buffer QC 
o Buffer QF 
o Buffer TE 
o LyseBlue 
o RNAse A (10 mg/ml or 100 mg/ml 
solution) 
Lumiglo elite (chemiluminescent substrate 
kit)* 
o LumiGLO Reserve Substrate Solutions 
A and B 
o Wash solution Concentrate 
One Shot TOP 10 Chemically Competent 
E.coli 
o TOP10 Chemically Competent E.coli 
cells 
o pUC19 Control DNA (10 pg/μl) 
o S.O.C Medium 
Platinum® SYBR® Green qPCR SuperMix-
UDG w/ ROX 
o Platinum® SYBR® Green qPCR 
SuperMix-UDG with ROX 
o 50 mM magnesium chloride (MgCl2) 
Platinum® Quantitative PCR SuperMix-UDG 
w/ROX 
o Platinum® Quantitative PCR 
SuperMix-UDG with ROX 
o 50 mM magnesium chloride 
Qiagen Plasmid Maxi Kit buffer 
 
 
 
o Buffer P1, resuspension: 50 mM Tris-
Cl, pH 8.0, 10 mM EDTA, 100 μg/ml 
Rnase A). 
o Buffer P2, lysis: 200 mM NaOH, 1% 
SDS 
o Buffer P3, neutralisation: 3.0 M 
potassium acetate pH 5.5 
o Buffer QBT, equilibration: 750 mM 
NaCl, 50 mM MOPS pH 7.0, 15% 
isopropanol 
o Buffer QC, wash: 1.0 M NaCl, 50 mM 
MOPS pH 7.0, 15 % isopropanol. 
o Buffer QF, elution: 1.25 M NaCl, 50 
mM Tris-Cl pH 8.5, 15% isopropanol. 
QIAquick Gel Extraction kit (250) o Buffer QG (contain chaotropic salts 
which are irritants) 
o Buffer PE (concentrate) 
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o Buffer EB 
o Loading Dye 
RNase-Free Dnase Set (50) o DNase I, RNase-Free (lyophilized) 
o Buffer RDD 
o RNase-Free Water 
RNeasy® Mini Kit (250)* o Buffer RLT (contains a guanidine salt) 
o Buffer RW1 (contains a guanidine salt) 
o Buffer RPE (concentrate) 
o RNase-Free Water 
SuperScript® VILO cDNA Synthesis kit o 10X SuperScript Enzyme Mix 
o 5X VILO Reaction Mix 
SuperScript III Reverse Transcriptase o SuperScript III RT, 200 U/μl 
o 5X First-Strand Buffer (250 mM Tris-
HCl (pH 8.3 at room temperature), 375 
mM KCl, 15 mM MgCl2) 
o 0.1 M DTT 
VentR® DNA Polymerase o MgSO4 (100 mM) 
o ThermoPol Reaction Buffer (10X) 
Wizard® Plus SV Minipreps DNA Purification 
System 
o Cell Resuspension Solution (CRA) 
o Cell Lysis Solution (CLA) 
o Neutralization Solution (NSB) 
o Column Wash Solution (CWA) 
o Alkaline Protease Solution 
o Nuclease-Free Water 
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8.1.3 Content of reagents, solutions and buffers 
Reagent/ solution Ingredients 
dNTP Mix, 10 mM Same amount dATP, dGTP, dCTP and dTTP 
Extraction buffer 35 mM SDS 
1 mM Na3VO4 
50 mM Tris pH 7.4 
4x loading buffer (for SDS-PAGE) 12.5 ml 1.0 M Tris-HCl pH 6.8 
40 ml 10 % SDS 
40 ml glycerol 99% 
0.4 ml bromphenol blue 
ad 100 ml dH2O 
Activate with 10% β-mercaptoethanol 
5x Running buffer (for SDS-PAGE) 124.5 mM Tris-base 
1.24 M glycine 
17.34 mM SDS 
Stored at RT 
10x Transfer buffer (for Western blotting) 312.86 mM Tris-base 
2.4 M glycine 
Stored at RT 
30% Acrylamidemix 29 g acrylamide 
1 g N,N`-methylenebisacrylamide 
Ad 100 ml with dH2O 
Stored in dark bottle at RT 
1.5 M Tris-HCl pH 8.8 181.71 g Tris-base 
900 ml dH2O 
Adjust pH to 8.8 with conc. HCl at RT 
Ad 1000 ml dH2O 
Stored at RT 
1.0 M Tris-HCl pH 6.8 60.57 g Tris-base 
400 ml dH2O 
Adjust pH to 6.8 with conc. HCl at RT 
Ad 500 ml with dH2O 
1x Transfer buffer activated  70 ml 10x Transfer buffer 
490 ml dH2O 
140 ml methanol 
Stored at 4˚C 
6% polyacrylamide gel, 10 ml 5.3 ml dH2O 
2 ml 30% Acrylamide/bisacrylamide ratio 
2.5 ml 1.5 M Tris-base pH 8.8 
100 μl 10% SDS 
100 μl 10% APS (fresh) 
8 μl TEMED 
10% polyacrylamide gel, 10 ml 4 ml dH2O 
3.3 ml 30% Acrylamide/bisacrylamide ratio 
2.5 ml 1.5 M Tris-base pH 8.8 
100 μl 10% SDS 
100 μl 10% APS (fresh) 
4 μl TEMED 
5% polyacrylamide gel (stacking gel), 3 ml 2 ml dH2O 
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0.5 ml 30% acrylamide 
0.375 ml 1.5 ml Tris-base pH 6.8 
30 μl 10% SDS 
30 μl 10% APS (fresh) 
2 μl TEMED 
LB medium  10 g tryptone 
5 g yeast extract 
10 g NaCl 
Ad 1000 ml dH2O 
Autoclave 
NP40 Extraction Buffer  2.5 ml 1M Tris pH 7.5 
1.5 ml 5 M NaCl 
2.5 ml 10% NP40 
0.5 ml 0.5 M NaF 
Ad 50 ml dH2O 
TAE buffer 0.04 M Tris-acetate 
1 mM EDTA 
8.1.4 Manufacturers: Instruments 
Instruments Manufacturer 
ABI Prism® 7900HT Sequence Detection 
System 
Applied Biosystems 
Biofuge Fresco Heraeus Instruments 
BlockHeater Stuart Scientific 
Centrifuge A14 Jovan 
Centrifuge 5417R Eppendorf 
Controlled environment incubator shaker New brunswick scientific co., inc. U.S.A. 
Countess Automated Cell Counter Invitrogen 
EnVision 2104 Multilabel Reader Perkin Elmer preciesly 
EpiChemi II Darkroom UVP Laboratory Products 
Fluoroskan Ascent FL Thermo Labsystems 
GLC-1 General Laboratory Centrifuge Sorvall 
GloMax®-Multi Detection System Promega 
Microplate reader- Multiscan EX Thermo Electron Corporation 
NanoDrop-1000 Spectrophotometer Saveen Werner 
Odyssey Infrared Imaging System LI-COR Biosciences 
Olympus IX81 Olympus optical co, ltd. 
PTC-100 Programmable Thermal Controller MJ Research Inc. 
RC 3B PLUS centrifuge Sorvall 
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Ultrospec 2100 pro UV/ Visible 
spectrophotometer 
Amersham Pharmacia Biotec 
Varifuge 3.0R Heraeus Instruments 
8.2  PROTOCOLS 
8.2.1 Mutagenesis reaction 
Mutagenesis, generating K575M-Smoothened (K575M-Smo) in pEF.6 vector: 
1. General composition for PCR-reactions: 
3 μl ThermoPol Buffer 
3 μl 10 mM dNTPs 
2 μl DMSO 
1 μl VENT DNA Polymerase 
2 μl 10 mM Primer FW (Forward) 
2 μl 10 mM Primer Rev (Reverse) 
X μl template (1 μg) 
Ad 30 μl dH2O 
In two separated tubes, add the reagents outlined in step 1 with the primer pairs (see 
table 3.1) and template specified under to generate the PCR-product I and II (see figure 
3.1): 
      I: Primer pair: R199W-FW & K575M-Rev (Table 3.1), Template: pEF.6 Smo wt 
(Expected PCR-product size1151bp).  
     II: Primer pair: K575M-FW & P755F-Rev (Table 3.1), Template pEF.6 Smo wt 
(Expected PCR-product size 558 bp). 
2. Amplify the PCR-products using the following program in the thermo cycler (PTC-
100TM Programmable Thermal Controller, MJ Research Inc). 
94˚C for 5 minutes 
94˚C for 30 seconds (denature DNA) 
55˚C for 30 seconds* (anneal primers)        30 cycles 
72˚C for 1 minute** (extend primers) 
72˚C for 5 minutes 
4˚C for ∞ 
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* Annealing: Change temperature according to primers character. 
** Extension: Change extension time when needed, approximately 1 min pr. 1000 bp 
extension. 
3. After ended PCR-reaction, analyse and purify the PCR-products from an agarose gel 
(Protocol 8.2.2 and 8.2.3). 
4. Use the flanking primers from step 1 and the purified PCR-products from step 3 to 
generate the final PCR-product. Prepare the PCR as outlined in step 1.  
III: Primer pair: R199W-FW & P755F-Rev (Table 3.1), Template: Purified PCR-
product I & product II (Expected PCR-product size 1689bp). Use the same program 
as in step 2. 
5. Analyse and isolate the PCR-product according to protocol 8.2.2 and 8.2.3. 
6. Digest the purified PCR-product from step 5 and pEF.6 Smo wt with the restriction 
enzymes Tth111I (4000 units/ml) and SphI (10.000 units/ml), as follows: 
30 μl template (~ 1 μg) 
1.5 μl Enzyme 1  
1.5 μl Enzyme 2 
0.5 μl BSA (100 μg/ml) 
5 μl Buffer according to the manufacturer`s specifications (see datasheet) 
Ad 50 μl nf-H2O 
7. Incubate the digestion reaction for 60 minutes at 37˚C. 
8. Analyse and isolate the digested products according to protocol 8.2.2 and 8.2.3. 
9. Use T4 DNA ligase to ligate the digested and purified PCR-product III and pEF.6 
Smo wt from step 8. Use re-ligation of the vector as negative control. Add the 
following components in two separate tubes: 
1. 2 μl T4 DNA ligase buffer 
1 μl T4 DNA ligase 
2 μl template 1 (e.g. digested and purified vector backbone) 
4 μl template 2 (e.g. digested and purified PCR-product) 
Ad 10 μl nf-H2O 
2. 2 μl T4 DNA ligase buffer 
1 μl T4 DNA ligase 
2 μl template 1 (digested and purified vector backcone) 
Ad 10 μl nf-H2O 
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10. Incubate the ligation reactions for 60 minutes at room temperature. 
11. Transform competent bacteria with the ligation mix from step 10 according to 
protocol 8.2.4 in this section. Alternatively: the ligation mixture could be stored at -
20˚C for later transformation of competent bacteria. 
 
8.2.2 Plasmid purification: Agarose gel electrophoresis 
1. Mount and level the casting tray. Place comb into place. 
2. Prepare 1 % agarose gel: 
1 g agarose 
100 ml 1 X TAE buffer 
10 μl ethidium bromide (10 μg/μl) 
Melt the agarose in microwave oven. Gently swirl the beaker and make sure all the agarose 
has melted. Cool the solution to approximately 50˚C before adding ethidium bromide. All 
handling with ethidium bromide should be done in ventilated hood due to its mutagenicity. 
Wear gloves. Mix thoroughly. 
3. Pour the solution into the casting tray. Carefully remove any air bubbles. Let the 
gel polymerize for approximately 30 minutes in room temperature. 
4. Transfer the gel to the electrophoresis tank after polymerization, and carefully 
remove the combs. Cover the gel completely with 1xTAE buffer. 
5. Load 30 μl of each sample (or adequate amount) onto the gel. Apply 12 μl of 100 
bp DNA ladder in the first well, containing: 
5 μl 100 bp DNA ladder (1 μg/μl) 
5 μl dH20 
2 μl DNA-loading dye 
 
6. Attach the electrophoresis apparatus to a power supply. Let the sample run 
through the gel at constant voltage of 100 V for approximately 50 minutes or as 
long as necessary for complete separation of the fragments. 
7. Visualize the bands under UV-light using the Epi Chemi II Darkroom (UVP- 
Ultra Violet Products, Laboratory Products). 
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8.2.3 Gel Extraction 
QIAquick Gel Extraction Kit Protocol using a microcentrifuge 
All centrifugation steps are carried out at 13.000 rpm (17.900 x g) in a conventional tabletop 
microcentrifuge at room temperature. 
1. Weigh the empty colourless tube and set the block heater at 50˚C. 
2. Excise the DNA fragment from the agarose gel with a clean, sharp scalpel.  
3. Put the gel slice in the colourless tube and weigh the tube again. 
4. Calculate the weight of the gelslice. 
5. Add 3 volumes of Buffer QG to 1 volume of gel (100 mg ~ 100 μl). 
6. Incubate at 50˚ C for 10 min (or until the gel slice has completely dissolved). To 
help dissolving the gel, mix by vortexing the tube every 2-3 minutes during the 
incubation.  
7. Add 1 gel volume of isopropanol to the sample and mix. 
8. Place a spin column in a provided 2 ml collection tube. 
9. To bind DNA, apply the sample to the column (max 800 μl), and centrifuge for 1 
minute. 
10. Discard the flow-through and place the column back in the same collection tube. 
11. Add 500 μl of Buffer QG to the column and centrifuge for 1 minute. 
12. Add 750 μl of Buffer PE to wash the column and centrifuge for 1 minute. 
13. Discard the flow-through and centrifuge the column for an additional 1 minute. 
14. Place the column into a clean 1.5 ml microcentrifuge tube. 
15. To elute DNA, add 30 μl of Buffer EB to the center of the membrane. Let the 
column stand for 1 minute, and then centrifuge for 1 minute.  
 
8.2.4 Transformation 
Competent cells are highly sensitive to changes in temperature and mechanical lysis caused 
by pipetting. Transformation was started immediately following thawing of the cells on ice. 
The bacteria suspension was mixed by swirling or tapping the tube gently, not by pipetting. 
 
Transforming chemically competent cells: One Shot TOP10 Competent Cells (Invitrogen) 
1. Centrifuge the vials containing the ligation mixture briefly and place on ice. 
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2. Thaw (on ice) one 50 μl vial of One Shot cells for two sets of ligation mix and 
carefully pipett 25 μl over to a new clean 1.5 ml tube. 
3. Add 5 μl ligation mix to 25 μl competent cells and mix by gently tapping. Store 
the remaining ligation mixture at - 20˚C. 
4. Incubate the cells on ice for 30 minutes. 
5. Heat-shock the bacteria for exactly 30 seconds at 42˚C in a water bath without 
shaking. 
6. Transfer the vial immediately to ice and incubate for 2 minutes without shaking. 
7. Add 250 μl of pre-warmed (room temperature) S.O.C medium to each vial. 
Sterilise the top of the S.O.C medium bottle with a gas-flame (S.O.C is a rich 
medium; sterile technique must be practiced to avoid contamination). 
8. Cap the tube tightly, and place the vials in a rack on its side and secure with 
parafilm to avoid loss of the vials. Shake the vials at 37˚C for exactly 1 hour at 
225 rpm in a shaking incubator. 
9. Spread 20 μl to 200 μl from each transformation vial on separate, labelled LB 
agarose-ampicillin (80 μg ampicillin/ml) plates. The remaining transformation 
mix may be stored at + 4˚C and plated out the next day, if desired. 
10. Invert the plates and incubate overnight at 37˚C. 
11. Pick single colonies, culture the bacteria 12-16 hours and isolate plasmid DNA 
with the Wizard Plus SV Minipreps DNA Purification System Kit (Protocol 
8.2.5). 
12. Prepare DNA for sequencing (protocol 8.2.9). 
 
8.2.5 Small-scale plasmid preparation                                                                                     
Wizard® Plus SV Minipreps DNA Purification System (Promega). 
1. Pick one well-isolated colony from a LB-agarose plate described in 8.2.4, and 
inoculate 3 ml LB-medium with ampicillin (80 µg/ml).  
2. Incubate the culture for 12-16 hours at 37˚ C in a shaking incubator (300 rpm). 
3. Transfer 1.5 ml of bacterial culture to a 1.5 ml microcentrifuge tube. Store the 
remaining bacterial culture at 2-8˚ C. Centrifuge the bacterial culture for 5 
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minutes at 10 000 x g in a tabletop centrifuge. Pour off the supernatant and blot 
the inverted tube on a paper towel to remove excess media. 
4. Add 250 μl of Cell Resuspension Solution and completely resuspend the cell 
pellet by vortexing or pipetting.  
5. Add 250 μl of Cell Lysis Solution, and mix the solution by inverting the tube 4 
times. Incubate the solution approximately 1-5 minutes until the cell suspension 
clears. 
6. Add 10 μl of Alkaline Protease Solution and mix by inverting the tube 4 times. 
Incubate for 5 minutes at room temperature. 
7. Add 350 μl of Neutralization Solution and immediately mix by inverting the tube 
4 times. 
8. Centrifuge the bacterial lysate at maximum speed (~ 14 000 x g) in a 
microcentrifuge for 10 minutes at room temperature. 
9. Insert one spin column into one 2 ml collection tube for each sample. 
10. Transfer the cleared lysate (approximately 850 μl) to spin column. Avoid 
disturbing or transferring any of the white precipitate with the supernatant. 
11. Centrifuge the supernatant at maximum speed for 1 minute at room temperature. 
Discard the flowthrough. Re-insert the spin column into the collection tube. 
12. Add 750 μl of column wash solution (previously diluted with 95% ethanol). 
13. Centrifuge at maximum speed for 1 minute at room temperature. Discard the 
flowthrough. Re-insert the spin column. 
14. Repeat the wash procedure using 250 μl of column wash solution. 
15. Centrifuge at maximum speed for 2 minutes at room temperature. 
16. Transfer the spin column to a new, sterile 1.5 ml microcentrifuge tube. 
17. Elute the plasmid DNA by adding 100 μl of nuclease-free water to the spin 
column. Centrifuge at maximum speed for 1 minute at room temperature. 
18. Measure the DNA concentration with Nano-drop-1000 (ND-1000 V3.5.2) or with 
Ultrospec 2100 UV spectrophotometer (Protocol 8.2.6). 
19. Store the purified plasmid DNA at -20˚ C. 
 
8.2.6 Quantification of DNA by UV analysis 
Ultrospec 2100 pro UV and NanoDrop-1000 
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Ultrospec 2100 pro: 
1. Tune the spectrophotometer to measure ODs at 230 nm, 260 nm and 280 nm. 
2. Clean the quartz cuvettes with dH2O. 
3. Dilute the plasmid sample 1:10 (DNA) with dH2O..  
4. Calibrate the apparatus using a blank containing only the solvent and then 
analyze the plasmid at the specified wavelengths. The readout may be as shown 
in figure 8.1. 
Sample 230 nm 260 nm 280 nm 260/230 260/280 Conc. 
Ref 0.000 0.000 0.000    
1 0.164 0.346 0.186 2.11 1.86 0.173 
2 0.190 0.361 0.200 1.90 1.80 0.181 
3 0.166 0.359 0.197 2.16 1.82 0.180 
4 0.172 0.355 0.196 2.06 1.81 0.177 
Figure 8.1: Example of spectrophotometer readout. The figure shows an example of readout from the 
Ultrospec 2100 Pro instrument providing absorbance data at 230, 260 and 280 nm. Column 3 shows the 
absorption at 260 nm (dilution 1:10), and from this we can derive ([DNA] (μg/μl) = OD260 x dilution /20) the 
concentration in column 7. Columns 5 and 6 indicate the purity of the sample which in this case is acceptable 
(OD260/OD280 ratio ~ 1.8 – 1.9, OD260/OD230 ratio ~ 1.8 – 2.2).  
 
Nanodrop: 
1. Wash the electrodes with water. 
2. Calibrate the apparatus by adding 2 μl dH2O. 
3. Add 2 μl RNase-free water (blank) to the electrode and measure the 
concentration. 
4. Wipe the electrode dry. 
5. Add 2 μl sample, and measure the RNA-concentration (ng/μl). 
6. Repeat step 4 and 5 for multiple samples. 
 
8.2.7 Sub-cloning 
Generation of EcoRI restriction sites in Smoothened wild type and R484W-, L514F-, 
S533N-, W535L-, K575M-Smo encoding cDNA: 
1. In a PCR-reaction use pEF.6 Smo wt, R484W-, L514F-, S533N-, W535L-, K575M-
Smo as template with the primer pEF.6 29U31 (forward; Table 3.1) and pEF.6 
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202L18 (reverse; Table 3.1). Prepare the PCR reaction as outlined in section 1.2, 
mutagenesis protocol step 1. 
2. Amplify the PCR-products using the thermo cycler-program as outlined in section 
1.2, mutagenesis protocol step 2. Change the extension time to 2.5 minutes. 
3. Analyse the products on 1% agarose gel, and use QIAquick Gel Extraction Kit to 
isolate the product from the gel (according to 8.2.2 and 8.2.3). The product size is 
2517 bp. 
 
Insertion of R484W-, L514F-, S533N-, W535L-, K575M-Smo and Smo wt in the p3xFLAG-
CMV-10 vector: 
4. In separate tubes, prepare restriction enzyme digestion of the PCR-products from 
step 3 and p3xFLAG-CMV-10 vector with EcoRI (10 units/μl) and XbaI (20000 
units/ ml) as outlined in mutagenesis protocol step 6 in section 1.2.  
5. Isolate the digested PCR-product and p3xFLAG-CMV-10 vector according to 
protocol 8.2.2 and 8.2.3. 
6. Ligate the digested and purified PCR-products and p3xFLAG-CMV-10 vector from 
step 5 as outlined in section 1.2, mutagenesis protocol step 9.  
7. Transform competent bacteria according to protocol 8.2.4 and use re-ligation of the 
p3xFLAG-CMV-10 vector as a negative control. Growth should not appear on LB-
agar-plate, since re-ligated vector is not a circulated plasmid that can express the 
ampicillin resistant gene. 
8. Isolate plasmid-DNA according to protocol 8.2.5. 
9. Prepare and send the plasmids for DNA-sequencing (protocol 8.2.9). 
10. Analyse the DNA-sequence and make maxiprep of the correct products (protocol 
8.2.8). 
 
8.2.8 Large-scale plasmid preparation 
HiSpeed Plasmid Maxi Kit (Qiagen) 
1. Transfer 1-2 ml culture (from miniprep protocol 8.2.5 step 3) of bacterial cells to 
250 ml LB medium with ampicillin in 2 l flask (The flask must be at least 4 times 
100 
the volume of the culture). Incubate the bacteria culture at 37°C in shaking 
incubator (approximately 300 rpm) 12-16 hours. 
2. Transfer the bacteria culture to centrifuge cups, and harvest the bacterial cells by 
centrifugation at 6000 x g for 15 min at 4°C (RC 3B PLUS centrifuge, Sorvall). 
3. Remove the supernatant and make sure that all traces of supernatant are 
completely removed.  
4. Resuspend the bacterial pellet in 10 ml Buffer P1 and transfer the suspension to 
50 ml tubes (Ensure that RNase A has been added to Buffer P1). 
5. Add 10 ml Buffer P2 and mix thoroughly by virgorously inverting the sealed tube 
4-6 times, and incubate at room temperature for 5 min. During the incubation 
prepare the filter cartridge: Screw the cap onto the outlet nozzle of the Maxi 
cartridgefilter. Place the cartridgefilter in a 50 ml tube. 
6. Add 10 ml chilled Buffer P3 to the lysate, and mix immediately and thoroughly 
by vigorously inverting 4-6 times. 
7. Pour the lysate into the barrel of the cartridge. Incubate at room temperature for 
10 minutes.  
8. Equilibrate a HiSpeed Maxi Tip by applying 10 ml Buffer QBT and allow the 
column to empty by gravity flow. 
9. Remove the cap from the filter outlet nozzle. Insert the plunger gently into the 
filter Maxi Cartridge and filter the cell lysate into the previously equilibrated 
HiSpeed Tip. Allow the cleared lysate to enter the resin by gravity flow. 
10. Wash the tip with 60 ml Buffer QC. 
11. Elute DNA with 15 ml Buffer QF in a 50 ml tube. 
12. Precipitate DNA by adding 10.5 ml RT isopropanol to the eluted DNA. Mix and 
incubate at room temperature for 5 min. 
13. Place the precipitator over a waste bottle and transfer the elute/isopropanol 
mixture into the 30 ml syringe, and insert the plunger. Filter the elute/isopropanol 
mixture through the precipitator using constant pressure. 
14. Remove the precipitator from the 30 ml syringe and pull out the plunger. Re-
attach the precipitator and add 2 ml 70% ethanol to the syringe. Wash the DNA 
by inserting the plunger and pressing the ethanol through the precipitator using 
constant pressure. 
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15. Remove the precipitator from the 30 ml syringe and pull out the plunger. Attach 
precipitator to the 30 ml syringe again, insert the plunger, and dry the membrane 
by pressing air trough the precipitator quickly and forcefully. Repeat this step. 
16. Dry the outlet nozzle of the precipitator with absorbent paper to prevent ethanol 
carryover. 
17. Remove the plunger from a new 5 ml syringe and attach the precipitator onto the 
outlet nozzle. Hold the outlet of the precipitator over a 1.5 ml collection tube. 
Add 1 ml TE Buffer to the syringe. Insert the plunger and elute the DNA into the 
collection tube using constant pressure. 
18. Remove the precipitator from the syringe, pull out the plunger and reattach the 
precipitator to the syringe.  
19. Transfer the eluate from step 18 to the 5 ml syringe and elute for a second time 
into the same 1.5 ml tube. 
 
8.2.9 DNA sequencing 
DNA sequencing was performed at Department of Molecular Biosciences, University of 
Oslo, Norway, having DNA sequencing as a core facility. 
1. Add following components were provided in separate tubes with the different 
primer sets:  
0.6 μg plasmid DNA 
2 μl 10 μM primer (Table 3.1) 
0.7 μl TRIS 100 mM 
Nuclease-free water ad 7.0 μl 
 
8.2.10 Thawing cells 
All cell culture procedures were carried out in a laminar airflow (LAF) bench to prevent 
contamination, using aseptic techniques. 
1. Remove a vial of frozen cells from the liquid nitrogen tissue culture library tank. 
Use forceps and place the vial in a water bath preheated to 37°C, until the cells 
are just thawed. Wear protective goggles and gloves, because the vial may 
explode under this procedure. 
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2. Transfer the thawed cell suspension to a 15 ml tube containing 5 ml preheated 
(37°C) complete growth medium.  
3. Centrifuge the suspension at 160 x g for 5 minutes. 
4. Discard the supernatant, and resuspend the pellet in 5 ml complete growth 
medium and transfer the suspension to a tissue culture dish (60mm). 
5. Culture the cells at 37°C in a humidified atmosphere of 5% CO2. 
6. When the cells are approximately 80% confluent, split the cells 1:4 and re-plate 
the cells on new tissue culture dishes (100 mm). 
 
8.2.11 Splitting cells 
For each 100mm dish: 
1. Aspirate off the growth medium and carefully wash the cells once with 10 ml 
0.9% NaCl. 
2. Add 1 ml trypsin-EDTA (200 mg/L) to cover the monolayer. Incubate the cells at 
37°C in a humidified atmosphere of 5% CO2 in air, until the cells detach 
(approximately 2-10 minutes depending on cell type and confluency). 
3. Remove the tissue culture plate from the incubator. Only if necessary give the 
plate a firmly tap on the side with the palm of the hand to promote the 
detachment. Check that the cells actually have detached in a microscope. 
4. Add 4 ml preheated (37°C) complete growth medium to the plates to neutralise 
the trypsin, and homogenise the cells by pipetting. 
5. Transfer the cell-suspension to a 15 ml tube. 
6. Centrifuge the suspension for 5 minutes at 160 x g. 
7. Remove the supernatant and resuspend the pellet in preheated complete growth 
medium.  
8. Plate the cells on new plates at a ratio of 1:3 to 1:12 (NIH/3T3), 1:4 to 1:10 (293 
EcR Shh) depending on the original confluency (approximately 2 million cells 
per 100 mm culture dish), or plate a specific number of cells after counting them. 
See protocol for cell counting. Add 10 ml preheated complete growth medium. 
9. Culture the cells at 37 °C in a humidified atmosphere of 5% CO2 in air. 
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8.2.11.1 Cell counting 
Countess Automated Cell Counter, Invitrogen 
1. Transfer 10 μl of trypan blue stain to 1.5 ml eppendorftubes for each cell-line to 
be counted.  
2. Add 10 μl of the cell suspension, from step 7 in protocol for splitting cells 
(8.2.11), to the 1.5 ml tubes with trypan blue stain, and mix well by pipetting.  
3. Add 10 μl of the sample mixture to the chamber ports on one side of the Countess 
cell counting chamber slide (The two chambers of the slide are labelled “A” and 
“B” for easy tracking of the samples). 
4. Insert the chamber slide into the slide inlet on the instrument. There will be a soft 
click, confirming that the slide is correctly inserted. 
5. Press the “Count Cells” button for the cells to be counted (cells/ml). Live cells 
have bright centres and dark edges, and dead cells have a uniform blue colour 
throughout the cell with no bright centres.  
6. Seed cells according to table 8.1. 
 
Table 8.1: Cell counting  
Experiment Cell type Number of cells/dish 
(well) 
Culture dish size 
Isolation of RNA for RT-
PCR 
NIH/3T3 200 000 -400 000  
100 000- 300 000  
60mm 
6-well plate 
Gene reporter assay 
(Lucifease assay) 
NIH/3T3 20 000  96-well plate 
Generation of Shh-
conditioned medium 
293 EcR Shh* 1x106  100 mm 
* Culture 1x106 cells in 100 mm dish for 24h, change the medium to 7 ml complete medium 
(10% FBS-DMEM) supplemented with 5μM Ponasterone A. 
8.2.12 Freezing cells 
For each 100 mm plate: 
1. At 60-70% cell confluence (log phase), split the cells according to protocol 
8.2.11, protocol step 1-7. 
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2. Resuspend the cells in 0.5 ml complete medium (without selection antibiotics), 
place the cells on ice and add 0.5 ml ice-cold cryoprotective medium containing 
15% DMSO. 
3. Carefully transfer the cell suspension to a cryotube kept on ice. 
4. Place the cryotube in a closed styrofoam box at –70 ºC, to let the temperature 
slowly decrease over night. Transfer the frozen cells to the liqid nitrogen tissue 
culture library tank for long term storage. 
 
8.2.13 Transfecting cells 
1. In a 100 mm tissue culture plate, seed 5x105 cells in 10 ml complete growth medium. 
2. Culture the cells at 37˚C in a humidified atmosphere of 5% CO2 in air until 70-80 % 
confluence, usually accomplished within 18-24 hours. 
3. For each transfection sample (for each 100 mm dish of cells) prepare the following 
solutions in two separate sterile tubes: 
 
Solution A: 6 μg of DNA + 600 μl OPTIMEM. 
Solution B: 15 μl Lipofectamine 2000 + 600 μl OPTIMEM. Mix Lipofectamine 2000 
gently before use by inverting the tube 4-6 times.  
 
4. Incubate for 5 minutes at room temperature. 
5. Combine the solution A and B from step 3. Mix gently and incubate for 20 minutes at 
room temperature. 
6. Aspirate the growth medium, and wash the cells with 10 ml 0.9% NaCl. 
7. Add 4.8 ml 5% NCS-DMEM to each culture dish with cells. 
8. Overlay the transfection solution onto the cells. 
9. Incubate at 37˚C in a humidified atmosphere of 5% CO2 in air overnight. 
10. Replace the transfection medium with 10 ml complete growth medium per tissue 
culture plate. 
11. Incubate at 37˚C in a humidified atmosphere of 5% CO2 in air overnight. 
12. Selecting stably transfected cells: Replace the growth medium with 10 ml 5% NCS-
DMEM supplemented with G-418 (0.8mg/ml) twice a week, until the untransfected 
cells have died.  
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8.2.14 Generation of monoclonal cell lines 
1. For each polyclonale cell-line, plate the cells at low density (20 000 cells per 100 mm 
tissue culture dish), and add 10 ml complete medium. Plate one tissue culture plate 
with 20 000 untransfected cells for control.  
2. Grow the cells in the presence of antibiotics (G-418, 0.8 mg/ml) at 37˚C in a 
humidified atmosphere of 5% CO2 in air, until the untransfected cells have died.  
3. Under the microscope, mark single cell under at the bottom of the tissue culture 
plate. 
4. Let the single cells grow into colonies at 37˚C in a humidified atmosphere of 5% 
CO2 in air.  
5. Under the microscope, select several independent colonies from the previously 
marked single cells. Use a pen to make a circle around separate colonies at the 
bottom of the tissue culture plate. 
6. Aspirate medium, and wash the cells with 10 ml 0.9% NaCl. 
7. Dip the lower rim of the cloning cylinders           in silicon, and place it over the 
marked cell colonies.  
8. Add two drops of trypsin-EDTA (200ml/L), and incubate the cells at 37°C in a 
humidified atmosphere of 5% CO2 in air, until the cells detach. 
9. Transfer the detached cells from one cloning cylinder to one well in a 6-well plate, 
and add 1.5 ml complete growth medium.  
10. Culture the cells at 37°C in a humidified atmosphere of 5% CO2 in air. 
 
8.2.15 Transfection for reporter gene assay (transient transfection) 
1. In a 96-well, seed 20 000 cells per well in 200 μl complete growth medium. 
2. Culture the cells at 37˚C in a humidified atmosphere of 5% CO2 in air until 70-80 % 
confluence, usually accomplished within 18-24 hours. 
3. Transfection-mix per well: 
30 μl OPTIMEM 
0.1 μg pGL4.74 Renilla Luciferase  
0.2 μg Gli BS-luciferase 
0.75 μl Lipofectamine 2000 
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Dilute Lipofectamine 2000 in OPTIMEM, mix and incubate for 5 minutes at room 
temperature before adding the DNA to the Lipofectamine 2000/OPTIMEM-solution, 
and incubate for 20 min. 
4. Rinse the cells in 0.9% NaCl and completely remove the solution. 
5. Add 70 μl complete growth medium to each well. 
6. Add 30 μl transfection-mix to each well. 
7. Culture the cells at 37˚C in a humidified atmosphere of 5% CO2 in air overnight.  
8. Stimulate cells according to protocol 8.2.16. 
 
8.2.16 Stimulation and harvesting of cells for gene reporter assay 
1. Use the transiently transfected cells from protocol 8.2.15. Aspirate the medium and 
wash with 100 μl 0.9% NaCl. 
2. Add 200 μl 0.5% NCS-DMEM to cells seeded in rows A-D (in a 96-well plate), and 
treat the cells in rows E-H with a mixture of 100 μl Shh conditioned medium, and 
100 μl 0.5% NCS-DMEM . Carefully add the stimulation mixture into the wells and 
tilt the plate to make sure that the medium are evenly distributed in the wells. 
3. Incubate overnight at 37˚C in a humidified atmosphere of 5% CO2 in air. 
4. Perform the gene reporter assay (protocol 8.2.17). 
 
8.2.17 Gene-reporter assay: Luciferase assay 
Dual-Luciferase® Reporter 1000 Assay System. 
Cell lysis: 
1. Thaw 5X PLB and prepare sufficient amount of 1X PLB (20 μl per well) by diluting 
in dH2O. 
2. Completely remove the medium from the cells. Wipe the 96-well plate on a paper. 
3. Add 200 μl 1xPBS to each well to rinse the cells 
4. Completely remove PBS.  
5. Add 20 μl 1xPLB to each well and place the 96-well plate on a shaker at room 
temperature for 20 minutes. 
6. Dispense 10 μl cell lysate into white opaque luminometer microtiter 384 plate (and 
20 μl for 96 well-plate). 
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Reagent preparation: 
7. Prepare Luciferase assay reagent II. Resuspend lyophilized Luciferase Assay 
Substrate in 10 ml of Luciferase Assay Buffer II and label “LAR II”. When using a 
384-well plate, 25 μl “LAR II” is needed for each well, and for 96-well plate, 50 μl is 
needed per well. About 1 ml “LAR II” in excess is also needed to tube volume for 
luminometer for both plates. 
Dual-luciferase measurement: 
8. Turn on the luminometer and prime both injectors with LAR II and Stop & Glo 
Reagent.  
9. Program the luminometer to perform 2-second premeasurement delay, followed by a 
10-second measurement period for each reporter assay, and initiate the measurement: 
o Injecting Luciferase Assay Reagent II (LAR II) 
o Measuring firefly luciferase activity for 10 seconds 
o Injecting Stop and Glo Reagent 
o Measuring Renilla luciferase activity for 10 seconds 
After use wash the injectors 
10. Place the tubes for both injectors in a 50 ml tube containing dH2O. Select flush/wash 
injectors from the menu. Repeat this wash step with 70% EtOH, and one more time 
with dH2O. Perform a final “wash” with air to empty and dry the injector tubes. 
 
8.2.18 RNA isolation 
1. Remove the medium from the wells in a 6-well plate and wash the cells twice with 1 
ml 0.9 % NaCl 
2. Add 200 μl trypsin-EDTA (200mg/L) to each well. 
3. Incubate at 37˚C until the cells detach. 
4. Add 1 ml complete growth medium. 
5. Transfer the cells to an RNase-free 1.5 ml tube, and centrifuge the cells at 4000 rpm 
for 5 minutes. 
6. Add 10 μl β-mercaptoethanol (β-ME) per 1 ml Buffer RLT. 
7. Completely aspirate the supernatant and resuspend the cell pellet from step 5 in 350 
μl buffer RLT. Vortex for 1 minute. 
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8. Homogenize the lysate by passing it through a blunt 20-gauge needle (0.9 mm 
diameter) at least 5 times. Fit the needle to a RNase-free syringe. 
9. Add 350 μl (1 volume) of 70 % ethanol to the homogenized lysate, and mix well by 
pipetting. Do not centrifuge. 
10. Transfer up to 700 μl of the sample to the spin column placed in a 2 ml collection 
tube. Centrifuge for 15 sec at ≥10 000 rpm. Discard the flow-through. 
DNase-digestion (elimination of genomic DNA contaminations): 
11. Add 350 μl Buffer RW1 to the spin column. Centrifuge for 15 s at ≥10 000 rpm. 
Discard the flow-through.  
12. Add 10 μl DNase I stock solution to 70 μl Buffer RDD. Mix gently by inverting the 
tube. Centrifuge briefly to collect residual liquid from the sides of the tube. 
13. Add the DNase I incubation mix (80 μl) directly to the spin column membrane. 
Incubate the samples for 15 min at room temperature. 
14. Add 350 μl Buffer RW1 to the spin column. Centrifuge for 15 sec at ≥10 000 rpm. 
Discard the flow-through. 
15. Add 500 μl Buffer RPE to the spin column. Centrifuge for 2 min at ≥10 000 rpm.  
16. Place the spin column in a new 1.5 ml collection tube. Add 40 μl RNase-free water 
directly to the spin column membrane. To elute the RNA, centrifuge the spin column 
for 1 min at ≥10 000 rpm. 
17. Determine the RNA concentration and quality using Ultrospec 2100 pro UV or 
Nanodrop. (Protocol description 8.2.6). 
 
8.2.19 Determination of RNA purity, quality and concentration 
Agarose gel electrophoresis: 
1. Prepare 1% agarose gel according to protocol 8.2.2.  
2.  Prepare the RNA-sample as follows: 
1 μg total RNA  
RNase-free water ad 5 μl 
2 μl formamid 
Incubate the mix at 65˚C for 10 minutes, place on ice for 1 minute. Add 2 μl loading 
buffer (1:6) to each sample, vortex and briefly centrifuge the sample. Load 9 μl of 
each sample onto the 1% agarose gel. Apply 12 μl of 100bp DNA ladder in one well. 
109 
3. Run electrophoresis at 50-90 V for 35 minutes. 
4. Visualize RNA under UV light. 
 
8.2.20 First strand cDNA synthesis 
1. Add the following components to nuclease-free microcentrifuge tubes: 
Oligo (dT) 1 μl  
10 mM dNTPs                                                              1 μl  
Total RNA in RNase-free water 2.5 μg Mix 1 
RNase-free water ad                                   11 μl  
 
2. Incubate the samples at 65 ˚C for 5 minutes (PTC-100 Programmable Thermal 
Controller, MJ Research) and cool down on ice for 2 minutes. 
3. Briefly centrifuge the samples to collect the contents in the bottom of the tubes 
(Biofuge Fresco, Heraeus Instruments). 
4. Make reverse transcriptase (+RT) reaction buffer as follows: 
5X First-Strand Buffer                                                 4 μl  
0.1 M DTT 1 μl Mix 2 
RNase Out Recombinant Rnase Inhibitor (40 U/μl) 1 μl  
SuperScript III RT (200 U/μl) 1 μl  
 
5. Make reaction buffer without reverse transcriptase (-RT) according to (+)RT mix 
prepared in step 4, but replace SuperScript III RT and RnaseOut by DNase-free 
water. 
6. Mix gently by pipetting. 
7. Add 7 μl Mix 2 to each tube from step 4. Mix gently by pipetting.  
8. Incubate samples in a Programmable Thermal Controller at: 
25 ˚C 5 minutes 
50 ˚C 60 minutes 
70 ˚C 15 minutes (Inactivate the reaction) 
4 ˚C End 
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8.2.21 RT-PCR 
Making a standard curve for real-time quantitative RT-PCR 
Pool 2-5 μl from fifteen to twenty RNA samples, enough to dispense 2.5 μg RNA in six 
tubes. Carry out first strand cDNA synthesis as described. 
1. Pool the cDNA synthesised from the pooled RNA samples. 
2. Make the following dilutions in separate tubes (Table 8.2): 
 μg/tube μl cDNA μl nuclease-free water 
Tube # 1 5 μg 120 μl cDNA 165 μl 
Tube # 2 2.5 μg 100 μl of tube #1 100 μl 
Tube # 3 1.25 μg 100 μl of tube #2 100 μl 
Tube # 4 0.625 μg 100 μl of tube #3 100 μl 
Tube # 5 0.31 μg 100 μl of tube #4 100 μl 
Tube # 6 0.15 μg 100 μl of tube #5 100 μl 
Table 8.2: Making a standard curve for real time RT-PCR. 
 
Real-time quantitative Reverse Transcriptase-PCR  
1. After reverse transcription reaction make dilution A for analyses of the gene of 
interest (SYBRgreen) and dilution B for standard curve analyses (GAPDH).  
Dilution A: Dilute each template (+ and – RT) with 75 μl RNase-free water: 
20 μl cDNA sample from protocol 1.7.2.4 step 8 (+ or – RT samples) 
75 μl RNase-free water 
Dilution B:  
5 μl Dilution A (+RT-samples and standard curve samples) 
200 μl RNase-free water 
Vortex the diluted samples. Dilution B is used for highly expressed genes normally 
used as “normalisation” genes.  
Store the diluted samples at -20˚C. 
2. For probe-based RT-PCR (of GAPDH): 
Mix the following volumes (μl) of the given components (Table 8.3): 
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Components μl per well Number of samples (X)x 3 
(triplicates) + 2 blanks x3 + 10 
(excess) 
GAPDH-mix 
(Column 1 x 
Column 2) 
RNase-free water 3.0 μl/well Xx3 + 2x3 + 10  X μl 
Forward primer (10 μM) 0.45 μl/well Xx3 + 2x3 + 10  X μl 
Reverse primer (10 μM) 0.45 μl/well Xx3 + 2x3 + 10  X μl 
Probe TaqMan (5 μM) 0.6 μl/well Xx3 + 2x3 + 10  X μl 
Platinum®SuperMix 
(Invitrogen) 
7.5 μl/well Xx3 + 2x3 + 10  X μl 
cDNA 3.0 μl/well Xx3 + 2x3 + 10  X μl 
Table 8.3: GAPDH-mix 
Use a multi-channel automated pipette and dispense 12 μl per well of the reaction 
mix in triplicates in a 384-well PCR plate. Add 3 μl cDNA template (dilution B) per 
well. Keep the samples and plates on ice while working. 
 
3. For SYBR-green based RT-PCR (of hSmo, mPtch, mGli). 
Mix the following volumes (μl) of the given components (Table 8.4): 
Components μl per well Number of samples 
* 3 (triplicates) + 2 
blanks*3 + 10 
(excess) 
SYBR-green-mix 
(Column 1 x 
Column 2) 
RNase-free water 0.6 μl/well Xx3 + 2x3 + 10 X μl 
Forward primer (10 μM) 0.45 μl/well Xx3 + 2x3 + 10 X μl 
Reverse primer (10 μM) 0.45 μl/well Xx3 + 2x3 + 10 X μl 
Platinum®SYBR® Green 
Super Mix (Invitrogen) 
7.5 μl/well Xx3 + 2x3 + 10 X μl 
cDNA 6.0 μl/well Xx3 + 2x3 + 10 X μl 
Table 8.4: SYBR-green-mix 
Use a multi-channel automated pipette and dispense 9 μl per well of the above 
reaction mix in triplicates in a 384-well PCR-plate. Add 6 μl cDNA template 
(dilution A) per well in triplicates. Keep the samples and plates on ice while working. 
4. Cover the PCR plate with optically clear sealing tape (Sarstedt) and centrifuge by 
using a Varifuge 3.0R (Heraeus Instrument) to collect the sample in the bottom of the 
well and remove air bubbles. 
5. Run real-time quantitative PCR (ABI Prism 7900HT Sequence Detection System, 
Applied Biosystems) with the following cycling parameters: 
50˚C 2 minutes  
95˚C 10 minutes  
95˚C 15 seconds 40 cycles 
60˚C 60 seconds  
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An additional dissociation step was added to the SYBRgreen analyses. The specificity of the 
RT-PCR products was verified by this melting-point analysis, showing only one top when 
having specific products. 
8.2.22 Protein concentration determination 
Prepare samples A-F for a standard curve from BSA protein stock 2 mg/ml, according to 
table 8.5. 
Standard Final BSA  
concentration (μg/ml) 
BSA  Water 
A 
B 
C 
D 
E 
F 
1500  
1000  
750  
500  
250  
125  
375 μl of stock BSA 
325 μl of stock BSA 
175 μl of A 
325 μl of B 
325 μl of D 
325 μl of E 
125 μl 
325 μl 
175 μl 
325 μl 
325 μl 
325 μl 
Table 8.5: Preparation of BSA for standard curve in protein concentration determination assay. 
1. Load a flat bottom 96-well plate with 20 μl standard solutions in duplicates, and 5 μl 
samples in triplicates as shown in figure 8.2. 
2. Mix 25 ml of BCAssay Reagent A with 500 μl of reagent B (BCAssay: protein 
quantitation kit, Uptima) for each 96-well plate. 
3. Add 200 μl of the reagent mix to each well. 
4. Incubate at 37˚C for 30 min. 
5. Allow the 96-well plate to obtain room temperature. 
6. Read the absorbance with a plate spectrophotometer at 570 nm. 
 1      2 3   4   5 6   7   8 9   10   11 12 
A dH2O Sample # 1 Sample # 9 Sample # 17 None 
B Standard F Sample # 2 Sample # 10 Sample # 18 None 
C Standard E Sample # 3 Sample # 11 Sample # 19 None 
D Standard D Sample # 4 Sample # 12 Sample # 20 None 
E Standard C Sample # 5 Sample # 13 Sample # 2 None 
F Standard B Sample # 6 Sample # 14 Sample # 22 None 
G Standard A Sample # 7 Sample # 15 Sample # 23 None 
H Blank Sample # 8 Sample # 16 Sample # 24 None 
Figure 8.2: Layout of a flat bottom 96-well plate for protein measurement. 
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8.2.23 SDS-PAGE 
Sample preparation 
1. Based on protein concentration determinations, transfer equal amounts of proteins to 
1.5 ml tubes, one for each sample. 
2. Dilute the samples with harvesting solution to ensure equal volume of each sample. 
3. Add 4x loading buffer (LB), activated with 10 % β-mercaptoethanol, which equals ¼ 
of the total sample loading volume.  
4. Vortex and boil the samples at 95˚C for 5 minutes in a heating block.  
5. Centrifuge the samples at 14000 rpm for a few seconds to collect the sample in the 
bottom of the tube. 
6. Load the samples (15 μl) on polyacrylamide gels. The remaining sample volume may 
be stored at -20˚C for later analyses.  
 
Pouring and running SDS-polyacrylamide gels 
1. Wash glass plates, one long with attached spacers and one short for each gel, three 
times with water and 70% ethanol. 
2. Assemble the glass plates and place them in the minigel holder, ensure that the 
bottom edges of the two plates are well aligned. Blow through the assembled glass 
plates with high pressure air to remove any remaining paper fibres. Clip the 
assembled glass plates into the casting stand. 
3. Prepare resolving gel solution (see composition in appendix 8.1.3) of desired 
acrylamide concentration according to the size of the proteins to be separate in a 50 
ml tube (add APS and TEMED imidiately before casting to avoid to early 
polymerization). 
4. Mix the solution by gently inverting the 50 ml tube without making any air bubbles, 
and pour the resolving gel solution between the assembled glass plates 
(approximately 4 ml). Leave sufficient place for the stacking gel. 
5. To ensure a flat surface, carefully overlay the acrylamide solution with 100-150 μl n-
butanol. 
6. Let the acrylamide solution polymerize for approximately 30 minutes. 
7. Wash away the n-butanol with water and remove remaining water with a 3MM filter 
paper without touching the gel. 
8. In a 50 ml tube, prepare 5% polyacrylamide stacking gel solution as outlined in 8.1.3. 
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9. Pour the stacking gel solution directly on the polymerized resolving gel and carefully 
insert the teflon comb to avoid trapping of air bubbles. Let the stacking gel 
polymerize for approximately 20-30 minutes at room temperature. 
10. Carefully remove the comb after the stacking gel has polymerised. 
11. Place the gels in the electrophoresis chamber. 
12. Fill the electrophoresis tank chambers with 1x Running buffer and wash the wells. 
13. Load 15 μl/well of protein samples, and 7 μl/well of molecular weight standard 
solution (Precision Plus Protein Dual Color Standards, Bio-Rad).  
14. Attach the electrophoresis apparatus to a power supply, and run the protein samples 
through the stacking gel (thickness 0.75 mm) at constant current (A) of 20 mA. 
Increase the current to 45 mA when the blue dye front has reached the resolving gel. 
Run the gel until the dye front reaches the bottom of the resolving gel. 
 
8.2.24 Western blotting 
Wet transfer 
1. For each gel, prepare one PVDF-membrane and six pieces of 3MM paper to the size 
of the resolving gel. 
2. To enable correct orientation of the membrane label on the upper right corner with 
number and F (facial side).  Labelling with the letter F ensures the correct orientation 
of the membrane. 
3. Activate the PVDF-membrane by submerging in methanol for approximately 20 
seconds. 
4. Place the membrane, filter papers and two porous pads for each blot in 700 ml 
transfer buffer in refrigerator. 
5. Prepare a transfer sandwich consisting of one porous pad, 3x 3MM filter papers, 
polyacrylamide gel, PVDF membrane, 3x 3MM filter papers and one porous pad.  
6. Place the transfer sandwich in the transfer apparatus containing pre-chilled transfer 
buffer with the membrane facing the red electrode (anode). Also add an ice block and 
a magnetic stir in the apparatus.  
7. Electroblot the proteins from the polyacrylamide gel to the membrane for 45 minutes 
at constant current (400 mA) and constant stirring. 
115 
8. After completing the transfer, open the transfer sandwich and directly put the 
membrane in 5% dry milk solution (or Odyssey blocking buffer). 
9. Block the membrane for 1 hour with slow aggitation at room temperature. 
 
Incubation with primary and secondary antibodies 
1. Dilute the desired primary antibody in 5 ml 5 % dry milk in PBS (or Odyssey 
blocking buffer) with 0.05 % Tween 20 (Table 8.6). 
2. Place the membrane in a plastic bag sealed on three sides, fill with the primary 
antibody solution from step 1 and seal the last side of the bag. Avoid trapping air 
bubbles inside the sealed bag. 
3. Incubate membrane over night at 4˚C on a tumbler. 
4. Wash the membrane for 3 x 6 minutes, with slow wagging, in PBS added 0.05 % 
Tween-20, at room temperature. 
5. Incubate the membrane in 5% dry milk in PBS (or Odyssey blocking buffer with 0.02 
% Tween 20) with appropriate diluted secondary antibody (Table 8.6) corresponding 
to the primary antibody used in step 1. 
6. Incubate at room temperature for 1 hour (Using Odyssey: incubate the nitrocellulose-
membrane in a dark box, because the secondary antibodies are sensitive to light). 
 
Substrate incubation 
1. Wash the membrane for 3 x 6 minutes in PBS added 0.05 % Tween 20, with slow 
aggitation at room temperature (Odyssey: Skip step 2 and 4) . 
2. Prepare the substrate, LumiGLO Elite Chemiluminescent Kit, according to the 
manufacturers (KPL) instructions (3 ml LumiGLO Reserve Solution B, 1.5 ml 
LumiGLO Reserve Solution A). 
3. Carefully rinse the membrane in dH2O before incubating the membrane in the 
substrate solution for 1 minute.  
4. Place the membrane between two clean pieces of transparency film, remove air 
bubbles and excess substrate. 
5. Record an image of the blot with the UVP Bio-Imager or equivalent apparatus 
immediately after incubation with substrate.  
6. Odyssey: Record an image of the blot with the Odyssey Infrared Imaging System 
after rinsing the membrane in dH2O (step 2).  
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Antibody concentrations 
(All antibodies were diluted in 5% non-fat dry milk phosphate-buffered saline 
(PBS)/Tween 20 or Odyssey blocking buffer with 0.02 % Tween 20) 
  Antibody dilution 
Primary antibody 
(rabbit polyclonal 
Anti-Smo (Abcam)) 
1:1000 Smoothened protein 
Secondary antibody 
(Donkey anti-rabbit 
(HRP)) 
1:2000 
Primary antibody 
(Anti-FLAG M2 
antibody (Sigma)) 
1:1000 Smoothened flag tag 
protein 
Secondary antibody 
(Donkey anti-
mouse(IRDye)) 
1:20 000 
Table 8.6: Antibody concentrations (cat no., section 8.1.1). 
 
 
